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Small-molecule suppressors of 
cytokine-induced beta-cell apoptosis 
Abstract 
Type-1 diabetes is caused by the autoimmune destruction of insulin-producing beta 
cells in the pancreas. Beta-cell apoptosis involves a complex set of signaling cascades 
initiated by interleukin-1 (IL-1), interferon- (IFN-), and tumor necrosis factor- (TNF-
). IL-1 and TNF- induce NFB expression, while IFN- induces STAT1 activation. 
These cytokines lead to a decrease of beta-cell function. The goal of this thesis is to 
identify small-molecule suppressors of cytokine-induced beta-cell apoptosis using high-
throughput screening approach. Using the rat INS-1E beta-cell line, I developed an 
assay to measure cellular viability after 48 hours of cytokine treatment. I screened 
29,760 compounds for their ability to suppress the negative effects of the cytokines. I 
identified several compounds to be suppressors of beta-cell apoptosis. These efforts led 
to the discovery of GSK-3 and HDAC3 as novel targets for suppressing beta-cell 
apoptosis. 
I also followed up on BRD0608, a novel suppressor that increased ATP levels and 
decreased caspase activity in the presence of cytokines. To follow up this compound, 35 
analogs related to BRD0476 were synthesized using solid-phase synthesis and tested 
for their protective effects in the presence of cytokines. A structurally related analog, 
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BRD0476, was found to be more potent and active in human islets, decreasing caspase 
activation and increasing insulin secretion after a 6-day treatment.  
I performed gene-expression profiling of INS-1E cells treated with the cytokine 
cocktail in the absence or presence of 10M BRD0476. Gene-set enrichment analysis 
revealed that the gene sets most significantly changed by BRD0476 involved cellular 
responses to IFN-. I therefore assessed the effects of BRD0476 on STAT1 
transcriptional activity. Cytokine treatment increased the reporter-gene luciferase activity, 
while co-treatment with BRD0476 reduced this activity significantly.  
To identify the intracellular target(s) of BRD0476, I collaborated with the 
Proteomics Platform in Broad Institute using SILAC (stable isotope labeling by amino 
acids in cell culture). SILAC is a mass spectrometry-based method to identify proteins 
that bind a small molecule attached to a bead. Deubiquitinase USP9X was pulled down 
by BRD0476. Knock-down of USP9X by siRNA phenocopied the protective effects of 
BRD0476. Binding assays were performed to identify interactions between BRD0476 
and USP9X. 
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Thesis roadmap  
My thesis research entails (1) assay development toward screening for 
suppressors of cytokine-induced beta-cell apoptosis, (2) identification of HDAC3 as a 
target for suppressing cytokine-induced beta-cell apoptosis and (3) discovery and target 
identification of BRD0476 in suppressing cytokine-induced beta-cell apoptosis. 
Chapter 1 begins with an introduction to type-1 diabetes overview, pancreatic beta-
cell apoptosis and cytokine signaling pathways in beta cells. Subsequently, it introduces 
previous works using either genetic approaches or small molecules to suppress 
cytokine-induced beta-cell apoptosis. It ends with discussion of high-throughput screens 
performed in the context of beta cells. 
Chapter 2 describes assay development and execution of a small-scale pilot 
screen. I worked closely with Nicole Bodycombe, Hyman Carrinski and Dr. Paul 
Clemons in the Chemical Biology Program at the Broad Institute. They were largely 
involved in the computational chemical biological part of this chapter. This part of study 
was published in ACS Chemical Biology. 
Chapter 3 describes the effects of different HDAC inhibitors in cytokine-induced 
beta-cell apoptosis. Later, using siRNAs to knock down individual HDAC, HDAC3 was 
found to be a target for suppressing cytokine-induced beta-cell apoptosis. Most of the 
HDAC inhibitors used here were obtained from Drs. Tim Lewis, Ed Holson and Florence 
Wagner in Broad Institute. HDAC3-selective inhibitors were from Dr. Jacob Hooker in 
Massachusetts General Hospital. This part of study was submitted for publication in 
Chemistry & Biology. 
Chapter 4 describes a 29,760-compound high-throughput screen. Dr. Patrick 
Faloon was a “chaperon” from Chemical Biology Platform at the Broad Institute to help 
me finish the screen and analyze the screening data. BRD0608, a novel suppressor that 
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increased ATP levels and decreased caspase activity in the presence of cytokines, was 
discussed. To follow up this compound, 35 analogs related to BRD0476 were 
synthesized using solid-phase synthesis. Dr. Jeremy Duvall from Chemical Biology 
Platform at the Broad Institute worked closely with me for this part. The synthesis part of 
this chapter was published in ACS Medicinal Chemistry Letters. 
Chapter 5 describes the efforts to identify targets for BRD0476. Gene-expression 
profiles were performed as a service from Genome Analysis Platform in Broad Institute. 
Quantitative proteomics study is a collaboration with the Proteomics Platform at the 
Broad Institute. These two approaches led to the discovery of the JAK-STAT pathway 
and USP9X as putative targets for BRD0476. 
 
 
 
Chapter 1 Introduction to type-1 diabetes, cytokine-induced beta-cell apoptosis 
and small-molecule screening 
1.1 Type-1 diabetes overview 
Type-1 diabetes is one of the most severe chronic autoimmune diseases with 
30,000 new cases annually in the United States(1). It is caused by an immune 
destruction of the insulin-secreting beta cells in the islets of Langerhans within the 
pancreas. A number of effector molecules produced by immune cells that infiltrate 
pancreatic islets led to beta-cell death(2). Once beta cells are destroyed, type-1 diabetic 
patients lose blood glucose control, which can result in severe conditions including 
hyperglycemia, heart disease, blindness and kidney failure(3). Although type-1 diabetes 
is described as an autoimmune disease, the precise immunological, genetic and 
physiologic events that control the disease initiation and progression remain unclear. 
The current type-1 diabetes therapies are the insulin injection and islet transplantation(4-
5). Injection of recombinant insulin is used for patients to control their own blood glucose 
levels. However, if patients cannot ensure optimal glycemic control, complications would 
ultimately develop. Islet transplantation, on the other hand, provides a better regulation 
of blood glucose levels. However, due to the limited amount of qualified donor islet cells, 
islet transplantation is not available to most type-1 diabetes patients. Moreover, one-time 
transplantation is not enough for life-long insulin independence. 
Two key models of type-1 diabetes-the BioBreeding (BB) rat(6) and non-obese 
diabetic (NOD) mouse(2, 7)- have been widely used to study the pathophysiology of the 
spontaneous form of type-1 diabetes. The two models share many similarities in loci of 
genetic susceptibility and pathogenesis of the disease. Therefore, the current 
understanding about the disease initiation and progression is mostly from the rodent 
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models. The studies in rodent models have shown that a breakdown of immune 
regulation results in the expansion of autoreactive CD4+ and CD8+ T cells, autoantibody-
producing B cells and activation of the innate immune system, which then collaborate to 
destroy the insulin-secreting beta cells(8-10). These results are consistent with human 
type-1 diabetes since 19 out of the 26 loci identified through genome-wide association 
study of human type-1 diabetes are associated with immune regulations(11-12). 
Observations in NOD mice have shown that the first immune cells to infiltrate the 
pancreatic islets are macrophages and dendritic cells(13). These cells probably migrate 
to the pancreatic lymph nodes to recruit CD4+ T cells(14). Consistent with this 
observation, removal of pancreatic lymph nodes at 3 weeks of age protects NOD mice 
against the development of insulitis(14). Macrophages and dendritic cells become 
antigen-presenting cells (APCs) and activate the naive Th0 CD4+ T cells via presentation 
of beta-cell antigens on their MHC class II molecules, favoring the differentiation in Th1 
cells(14). The Th1 CD4+ T cells then secrete interleukin-2 (IL-2) and interferon-gamma 
(IFN-gamma) which further stimulate APC to secrete other cytokines, such as IL-1beta 
and tumor necrosis factor-alpha (TNF-alpha) and nitric oxide (NO). These secreted 
cytokines activate the migration of CD8+ cytotoxic T cells into the islets and stimulate 
beta cells to release chemokines and IL-15 which further induce the activation of 
immune cells(15). 
Usually, more than 70% of the beta-cell population is destroyed upon diagnosis of 
type-1 diabetes(16). Apoptosis is the main form of beta-cell death observed in rodent 
models and in human islets from T1D patients(17). The mechanisms of beta-cell 
destruction in T1D have not yet completely clarified, but pro-inflammatory cytokines, 
including IL-1beta, TNF-alpha and IFN-gamma, by the immune cells infiltrating the islet 
are main mediators for the destruction of beta cells(17). The aim of this thesis is to 
2
discover novel suppressors of cytokine-induced beta-cell apoptosis as probes to study 
beta-cell biology. 
 
1.2 Beta-cell apoptosis 
Apoptosis, or programmed cell death, normally describes the regulated death of a 
cell. When cells sense the “apoptosis signal”, they shrink and undergo processes 
including chromatin condensation, DNA degradation, and protein cleavage. Eventually, 
apoptotic cells are cleared by neighboring cells by phagocytosis. Apoptosis is different 
from necrosis, which would lead to cell swelling and disruption of organelles. It has 
become increasingly evident that beta-cell apoptosis contributes to the development of 
both type-1 and type-2 diabetes(16). In the case of type-1 diabetes, the mechanisms by 
which pancreatic beta cells are selectively killed by the immune system have been 
thought to involve several pathways including 1) expression of Fas ligand (FasL) and its 
receptor Fas at the surface of the activated CD8+ T-cells and pancreatic beta cells 
respectively; 2) secretion of perforin and granzyme B by activated CD8+ T-cells; 3) 
secretion of pro-inflammatory cytokines, including IL-1beta, IFN-gamma and TNF-alpha 
by the diverse immune cells infiltrating the islet (Figure 1-1) (17). Fas and FasL were 
expressed at the surface of beta cells and infiltrating T cells, respectively(18). Although 
the expression of Fas in beta cells is low, it was shown that Fas expression can be 
induced in rodent beta cells by IL-1beta and IFN-gamma(18). Activation of Fas by FasL 
converts pro-caspase-8 to active caspase-8. Caspase-8 then acts via the pro-apoptotic 
BH3-only Bcl family member Bid to induce permeabilization of the mitochondrial outer 
membrane and release of cytochrome c(19). Bid interacts directly with the pro-apoptotic 
effector Bcl protein Bax and activates its channel-forming functions in the outer 
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mitochondrial membrane. One study specifically overexpressed a dominant negative 
form of Fas in beta cells of the NOD mice and observed a delay of the onset of 
diabetes(20). This suggests a role of Fas in beta-cell apoptosis. Another pathway of 
beta-cell apoptosis in type-1 diabetes involves perforin and granzyme B, They are both 
cytotoxic components secreted by CD8+ T cells. Perforin is involved in pore formation 
across the plasma membranes of beta cells. This pore enables the entry of the serine 
protease granzyme B inside the cell. Granzyme B cleaves multiple substrates in beta 
cells, causing the cleavage and activation of several targets, such as effector caspases  
 
Figure 1-1. Effector molecules contributed to beta-cell apoptosis in type-1 diabetes 
and the BH3 only protein Bid. NOD mice without perforin have reduced diabetes 
incidence compared with normal NOD controls; however, they still developed severe 
insulitis(21). Pro-inflammatory cytokines are detectable during early stage of diabetes 
onset in both NOD mice and BB rats. Moreover, in vitro exposure of beta cells to IL-
1beta plus IFN-gamma causes functional impairment similar to those observed in pre-
diabetic animal models and human patients(22). Prolonged exposure of pro-
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inflammatory cytokine cocktails, but not each cytokine alone, converts the functional 
impairment to beta-cell death. The detailed effects of each cytokine in beta cells will be 
described in next section. 
Glucose toxicity, lipotoxicity, and ER stress are also some other mediators resulting 
in beta-cell apoptosis; however, they are more relevant in the situation of type-2 
diabetes(16, 23). Beta cells are very sensitive to glucose concentration because they 
need to regulate the blood glucose level by secreting insulin. In order to release insulin, 
glucose enters beta cells, undergoes glycolysis and the respiratory cycle and results in 
the generation of ATP inside the cell. High ATP levels can close the ATP-
dependent potassium channels, and the cell membrane depolarizes. On depolarization, 
voltage-controlled calcium channels open, calcium flows into the cells and beta cells 
release insulin. Constant high glucose levels can induce beta-cell apoptosis in several 
ways. First, reactive oxygen species (ROS) are generated by hyperactive mitochondria 
and ROS are toxic to beta cells(24). Constant high calcium ion levels are also toxic to 
the overworked beta cells(25). Moreover, prolonged hyperglycemia may induce Fas-
mediated beta-cell apoptosis. Although the importance of glucose toxicity in the 
development of diabetes is still debated, glucose toxicity is definitely one of the factors 
contributing to beta-cell death. Lipotoxicity is more or less thought to be related to type-2 
diabetes since obesity is thought to trigger the disease by causing hyperlipidemia and 
insulin resistance(23). Elevated fatty acids, such as palmitate and oleate, have direct 
toxic effects on beta cells, For example, palmitate activates caspase-3 dependent 
apoptosis pathway in beta cells(26). In another study, palmitate reduces the expression 
of Bcl-2, an antiapoptotic protein(27). Moreover, lipotoxicity is also thought to be 
synergistic with the detrimental effects of glucose toxicity(28). Fatty acids-induce beta-
cell death also occurs at the ER level, where fatty acid esterification happens(29). A high 
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fatty acid load would exceed the capacity of beta cell’s esterification capacity, impair ER 
function and lead to ER stress. When the ER cannot function well, lots of unfolded 
proteins are generated, which results in the unfolded protein response. Three ER-
signaling molecules, PERK, ATF6, and IRE1, trigger cellular responses and lead to beta-
cell apoptosis if the ER stress is not alleviated(29). ER stress has been proposed as the 
molecular mechanism linking obesity with insulin resistance but it is still debated(29). 
 
1.3 Cytokine signaling pathways in pancreatic beta cells 
Pro-inflammatory cytokines are thought to be the main mediators of beta-cell 
apoptosis, especially in the early stage of the disease. They induce stress-response 
genes that are either protective or deleterious for beta-cell survival. Gene-expression 
profile experiments revealed about 700 genes that are regulated after 1–24 hour of 
exposure to IL-1beta and IFN-gamma in rat beta cells(30). Among them, Nuclear Factor 
kappa B (NFκB) and STAT1 are the main regulators of the pathways triggered by these 
pro-inflammatory cytokines. Here, the pathways controlled by IL-1beta, IFN-gamma and 
TNF-alpha will be discussed (Figure 1-2). 
IL-1beta binding to its receptor (IL-1R) induces the formation of a multi-protein 
complex and activates TNF-receptor associated factor-6 (TRAF-6) by phosphorylation. 
TRAF-6 then activates the NFκB and the mitogen activated protein (MAPK) pathways. 
TRAF-6 activates the IkappaB kinase (IKK) complex, which then phosphorylates the 
inhibitors of NFκB, IκBs, causing their degradation. This event releases NFκB and 
initiates its translocation into the nucleus, where it regulates the transcription of target 
genes. Activation of the NFκB pathway causes apoptosis in pancreatic beta cells. 
Overexpression of an NFκB super-repressor protects rodent pancreatic beta cells 
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against cytokine-induced apoptosis(16). IL-1R deficient NOD mice present a delayed 
onset of diabetes, which further proves the role of IL-1beta in in vivo beta-cell 
 
Figure1-2. Cytokine signaling pathways in beta cells 
apoptosis(31). Moreover, blocking IL-1 signaling with an IL-1 receptor antagonist delays 
the onset of diabetes in NOD mice(31). IL-1beta also affects beta-cell function. For 
example, IL-1beta alone presents a progressive inhibition of glucose-stimulated insulin 
secretion (GSIS) in rodent beta cells(32). In human beta cells, IL-1beta, in combination 
with IFN-gamma, impairs conversion of pro-insulin into mature insulin and triggers beta-
cell apoptosis after 7 days(22).	  
IFN-gamma binding to its receptor, IFN-R, induces the recruitment of two members 
of the Janus kinase (JAK) family, JAK1 and JAK2. Once activated by phosphorylation, 
JAK1 and 2 recruit STAT1 and trigger its activation by phosphorylation. STAT1 then 
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homodimerizes and migrates to the nucleus where it regulates the expression of genes 
containing gamma-activated sequence (GAS) elements in their promoter. The JAKs also 
activate the extracellular signal-regulated kinase (ERK) in beta cells. Experiments using 
IFN-R deficient NOD mice has provided inconsistent results, with one study showing a 
marked inhibition of insulitis while the other has no changes in the prevalence of 
insulitis(33-34). However, inhibition of STAT1, the main signaling pathway of IFN-
gamma, by siRNA prevents cytokine-induced apoptosis in the rat beta-cell line INS-1 
(35). 
TNF-alpha binding to the TNF receptor 1 (TNF-R1) leads to its trimerization and 
recruitment of the adaptor protein TNF receptor-associated death domain protein 
(TRADD). TRADD then recruits TRAF-2 and the serine-threonine kinase Rip. TRAF-2 
collaborates with Rip to induce NFκB via activation of the IKK complex. Besides TRAF-
2-mediated events, TNF-R1 recruits FADD which in turn leads to pro-caspase-8 
recruitment and activation of effector caspases such as caspase-3. TNF-R1 deficient 
NOD mice fail to develop spontaneous diabetes, which indicates the role of TNF-alpha in 
beta-cell death(13). Consistent with this finding, anti-TNF-alpha antibodies block the 
development of diabetes in NOD mice(36). 
Although each cytokine triggers different pathways inside beta cells, their 
downstream effectors “crosstalk” with each other. Several studies observed synergistic 
effects of cytokines in causing beta-cell apoptosis in vitro(37). The resulting gene 
networks triggered by the cytokine cocktail are too complicated to select a single target 
for suppressing this cell death with small molecules. The next two sections will review 
up-to-date efforts in suppressing cytokine-induced beta-cell apoptosis using various 
approaches. 
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1.4 Genetic approaches to suppress cytokine-induced beta-cell apoptosis 
Because of the important roles of cytokines in causing beta-cell apoptosis, various 
genetic approaches have been used to suppress beta-cell death. As mentioned earlier, 
removal of cytokine receptors could either prevent or delay the onset of diabetes in NOD 
mice. However, since individual cytokine receptors are conserved in different cell types, 
universal blockage of cytokine receptors would affect the functions of these cytokines in 
other physiological events. The NFκB pathway is a key pro-apoptotic pathway induced 
by IL-1beta and TNF-alpha. Numerous studies investigated the potential of blocking 
NFκB pathway to suppress cytokine-induced beta-cell death. Among them, one study 
generated a transgenic mouse line expressing a degradation-resistant NFκB protein 
inhibitor (ΔNIκBα), acting specifically in beta cells, in an inducible and reversible 
manner(38). In vitro, islets expressing the ΔNIκBα protein were resistant to the 
deleterious effects of IL-1beta and IFN-gamma, as assessed by reduced NO production 
and beta-cell apoptosis. This study indicated the whole NFκB pathway as a possible 
target for suppressing beta-cell death induced by cytokines. Like the NFκB pathway, the 
JAK-STAT pathway is activated by IFN-gamma and would also lead to cell death 
eventually. When activated, STAT1 is a master transcription factor and regulates genes 
that have gamma-activating sequences (GAS) in their promoter regions. Therefore, a 
study used siRNA specific for STAT1 to transfect rat INS-1E cells to investigate the 
protective role of STAT1 knockdown for beta cells(35). siRNA-mediated STAT1 
knockdown protects INS-1E and primary rat beta cells against cytokine-induced 
apoptosis. This study suggested STAT1 as a target for suppressing beta-cell death 
induced by cytokines. Although STAT1 is an important protein in beta-cell biology and 
other human diseases, there is still no direct small-molecule inhibitor or binder in the 
9
literature to block the function of STAT1. Nevertheless, upstream proteins that regulate 
STAT1 activity such as JAKs were used to modulate STAT1 activities. 
In addition to targeting pathways or proteins that are directly activated by individual 
cytokines, other pathways related to apoptosis were also investigated in order to 
suppress beta-cell apoptosis. One study used adenovirus-mediated overexpression of 
the anti-apoptotic protein, Bcl-XL, to suppress apoptosis of rat RIN beta cells induced by 
cytokines(37). Considering these anti-apoptotic proteins are potential oncogenes, 
overexpression of these proteins does not seem to be a good approach in suppressing 
beta-cell death. One interesting study investigated the role of SIRT1, a class III histone 
deacetylase, in protecting beta cells(39). SIRT1 is known to interfere with the NFκB 
pathway and thereby thought to have an anti-inflammatory function. Adenovirus-
mediated overexpression of SIRT1 in RIN cells was able to suppress apoptosis induced 
by cytokines. Furthermore, resveratrol, a SIRT1 activator, could suppress beta-cell 
apoptosis in either RIN cells or isolated rat islets in this case. Follow-up experiments 
demonstrated that the mechanism under this protection was by suppressing the NFκB 
pathway probably through deacetylation of p65 by SIRT1. 
 
1.5 Small-molecule precedents to suppress cytokine-induced beta-cell apoptosis 
Because of the important roles of cytokines in mediating beta-cell death, 
researchers have been searching for small molecules that could suppress the effects of 
cytokines. Among these studies, most of them use natural products or plant extracts to 
suppress cytokine-induced beta-cell apoptosis. For example, extracts of Artemisia 
capillaries(40), St John’s wort(41), Radix asari(42), and natural products such as 
flavonoids were all reported to have protective effects in beta cells(43). The common 
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feature is that these compounds or extracts were demonstrated previously to be 
antioxidants or have anti-inflammatory effects in other cell types. Therefore, these are 
not designed specifically for pancreatic beta cells and would not have selective 
protection towards beta cells. Furthermore, the mechanisms of actions were not fully 
studied. Most of them were annotated in the paper as blockers of the NFκB-iNOS 
pathway. One particular polyphenolic flavonoid, silymarin, is a special example in this 
type of compounds(44). Silymarin has a strong antioxidant activity and exhibits 
anticarcinogenic, antiinflammatory, and cytoprotective effects. Matsuda et al. therefore 
studied the effect of silymarin on IL-1beta and IFN-gamma-induced beta-cell damage 
using RINm5F cells and human islets(44). Silymarin dose-dependently inhibited both 
cytokine-induced NO production and cell death in RINm5F cells. Furthermore, silymarin 
prevented cytokine-induced NO production and impairment of glucose-stimulated insulin 
secretion in human islets. These protective effects of silymarin were thought to be 
mediated through the suppression of JNK and JAK/STAT pathways. 
The most interesting findings so far in the literature of small-molecule suppressors 
of cytokine-induced beta-cell apoptosis are the histone deacetylase (HDAC) inhibitors, 
suberoylanilide hydroxamic acid (SAHA) and trichostatin A (TSA)(45). In 2007, Larsen et 
al. reported that in both INS-1 cells and primary rat islets, SAHA or TSA could prevent 
cytokine-induced beta-cell toxicity(45). This finding seems counterintuitive, because 
HDAC inhibitors were thought to induce apoptosis in different cell types. Moreover, 
SAHA was actually approved by the U.S. Food and Drug Administration (FDA) in 
October 2006 for the treatment of cutaneous T cell lymphoma (CTCL). However, in 
cytokine-treated beta cells, SAHA and TSA reduced the amount of apoptotic cells. The 
expression of iNOS was also reduced by the treatment, which led to lower production of 
nitric oxide. On the other hand, SAHA and TSA failed to restore glucose-simulated 
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insulin secretion, although they could restore the accumulation of insulin over a 24-hr 
period. A follow-up study in the literature demonstrated that another HDAC inhibitor, 
ITF2357, could normalize streptozocin (STZ)-induced hyperglycemia in mice at the 
clinically relevant doses of 1.25-2.5 mg/kg(46). In vitro, at 25 and 250 nmol/L, ITF2357 
increased islet cell viability, enhanced insulin secretion, reduced nitric oxide production, 
and decreased apoptotic cells. iNOS levels decreased in association with reduced islet-
derived nitrite levels. These results point to HDACs as potential targets for suppressing 
beta-cell apoptosis. The mechanism of its protective effect was considered to be down-
regulation of the NFκB pathway. Although similar positive effects of TSA or SAHA in 
cytokine-exposed cells were observed, minor toxicity on insulin secretion and apoptotic 
rate was observed in beta cell lines, especially with TSA. This may be due to the 
nonselective manner of these HDAC inhibitors. In summary, a number of efforts had 
been put in searching for small-molecule inhibitors of beta-cell apoptosis; however, there 
is still no systematic or large-scale approach to look for such inhibitors. 
 
1.6 Small-molecule screening in beta-cell biology 
Small-molecule high-throughput screening (HTS) is a method used for probe or 
drug discovery in both academia and pharmaceutical industry. This allows researchers 
to perform thousands to millions of chemical or biological tests in a relatively short time 
frame. The “hits” generated from HTS can be used as probes to study certain biological 
pathways or as drugs to cure certain diseases. 
Because of the power of HTS, several studies used this approach to generate 
probes for beta-cell biology. In 2009, Wang et al. screened ~850,000 compounds to 
identify small-molecule inducers of pancreatic beta-cell expansion(47). They found a 
group of dihydropyridine derivatives that was shown to reversibly induce beta-cell 
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replication in a mouse R7T1 beta-cell line by activating L-type calcium channels. Later, 
Chen et al. discovered a small molecule, (-)-indolactam V, capable of converting a 
heterogeneous population of embryonic stem cells (HUES 9 cells) towards a pancreatic 
cell fate by inducing Pdx1 expression(48). In 2010, Fomina-Yadlin et al. screened a 
30,710-compound library to identify BRD7389, a compound capable of inducing insulin 
mRNA and protein expression in the alphaTC1 cell line(49). Additionally, Kiselyuk et al. 
screened a library of 1,040 known drugs for modulators of human insulin promoter 
activity in the human fetal islet-derived T6PNE cell line, and found a class of 
phenothiazines that was able to activate the insulin promoter(50). However, no 
systematic screen for suppressors of cytokine-induced beta-cell apoptosis has been 
performed to date. 
 
1.7 Concluding remarks 
Beta-cell death, and the concomitant deficiency in insulin secretion, is a key feature 
of type-1 diabetes. For decades, the standard of care for this disease has been insulin 
therapy via intramuscular injection. Current approaches to develop new treatments have 
focused on islet transplantation and directed stem-cell differentiation, while many 
technological advances have focused on glucose detection and insulin delivery. 
Autoimmune-induced death of beta cells involves a complex set of signaling cascades 
initiated by IL-1beta, IFN-gamma and TNF-alpha. IL-1beta induces NFκB expression, 
while downstream activation of gene expression is thought to occur through nitric oxide 
signaling, which both increases the endoplasmic reticulum stress-response pathway and 
decreases beta-cell-specific functions; this pathway works together with IFN-gamma-
induced STAT-1 signaling to effect beta-cell death. Small molecules that increase beta-
cell survival will be beneficial to early-stage type-1 diabetic patients since there are still a 
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number of beta cells inside the pancreas and beta cells can be protected by preventing 
the attack from cytokines. Thus, the goal of my doctoral research is to develop a set of 
cell-based assays to identify small molecules capable of suppressing cytokine-mediated 
beta-cell death, and potentially of improving glycemic control in the context of the 
development of type-1 diabetes. This study is also one of the first large-scale efforts to 
screen for compounds with an impact on beta-cell biology. 
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Chapter 2: Assay development toward screening for suppressors of 
cytokine-induced beta-cell apoptosis 
2.1 Introduction 
As mentioned in Chapter 1, pro-inflammatory cytokines, IL-1beta, IFN-gamma 
and TNF-alpha, are main mediators in pancreatic beta-cell death in type-1 diabetes. 
Suppressors of beta-cell death could be used as valuable chemical probes to study 
beta-cell biology, or as therapeutic agents for type-1 diabetics in the future. In order to 
identify novel suppressors of cytokine-induced beta-cell death, I planned to use 
high-throughput screening (HTS) to identify such small molecules. HTS is a powerful 
method used by both academic and industrial researchers to screen for small 
molecules with desired properties from libraries of 10,000-1,000,000 compounds. 
Therefore, HTS requires high-throughput and miniaturized primary assays to 
complete the whole campaign in a manageable time. For this reason, I developed a 
suite of cell-based assays to probe for different aspects of beta-cell biology. Moreover, 
HTS requires a huge amount of cells for the campaign. Therefore, it is not practical 
and feasible to use primary beta cells in the primary screen. The choice of the right 
cell line is then crucial for the screening outcome. In this chapter, I will describe my 
efforts in using rat insulinoma cells, INS-1E, to develop four different high-throughput 
cell-based assays. Using cellular ATP levels as the primary readout, I screened a 
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library containing 2,240 compounds and measured the effects of top positive 
compounds in follow-up assays. These efforts led to the discovery of several 
previously unknown suppressors of cytokine-induced beta-cell apoptosis(1). 
 
2.2 Development of four assays in measuring different aspects of beta-cell 
biology in rat INS-1E cell line 
I sought to find a suitable cell line to mimic the physiologically relevant condition 
of the development of type-1 diabetes. Previous studies in the literature had used a 
few beta-cell lines in a two-day cytokine cocktail treatment to mimic physiological 
conditions(2-4). Therefore, I tested different cocktails of cytokines suggested in the 
literature in six different beta-cell lines. These are two rat insulinoma cells, INS-1E 
and RIN-m5f, three mouse insulinoma cells, MIN6, betaTC-6 and NIT-1, and one 
hamster insulinoma cell, HIT-T15. The first three cytokine cocktails tested were 
10ng/mL IL-1beta + 10ng/mL IFN-gamma, 2ng/mL IL-1beta + 50ng/mL IFN-gamma 
and 5ng/mL IL-1beta + 50ng/mL IFN-gamma (Figure 2-1). INS-1E and HIT-T15 are 
the best two cell lines in sensing cytokine cocktail, since the cellular ATP levels of 
treated cells were reduced to ~70% of the control cells (no cytokine treatment). Here, 
cellular ATP levels are measured using the commercial reagent CellTiter-Glo from 
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Promega. CellTiter-Glo contains luciferase and luciferin. When ATP is present, 
luciferase can convert luciferin to oxyluciferin and generate luminescence. The 
luminescence can be detected here to indicate the amount of ATP inside cells. 
 
Figure 2-1. Cell viability assay for six different beta-cell lines. CellTiter-Glo is a 
luciferase-based assay for cellular ATP levels, which can be used as a surrogate of cell 
viability. Higher luminescence signal corresponds to higher cell viability. Blue: no cytokine 
treatment; Pink: 10ng/mL IL-1beta and 10ng/mL IFN-gamma; Yellow: 2ng/mL IL-1beta and 
50ng/mL IFN-gamma; Cyan: 5ng/mL IL-1beta and 50ng/mL IFN-gamma. Concentrations are 
chosen from literature precedents. 
I decided to use INS-1E cells in future experiments for two main reasons. First, 
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INS-1E cells and their parental cell line, INS-1, were well-studied in the literature, 
giving us the opportunity to compare our finding with others in the literature in the 
same cell line. Second, INS-1E is a good cell line for measuring glucose-stimulated 
insulin secretion (GSIS)(5). When beta cells are in a low glucose condition (the fasting 
state), they only secrete a basal level of insulin. When the glucose level rises (after 
meal), beta cells secrete more insulin to reduce the blood glucose levels. The ratio of 
secreted insulin levels is called the stimulation index. In INS-1E cells, GSIS results in 
a stimulation index of greater than 3, which is more similar to primary beta cells 
compared to other beta-cell lines. Several groups have shown in the literature that 
INS-1E cells become apoptotic after 2-day cytokine treatments and their ability to 
secrete insulin in response of high glucose concentration is also impaired due to 
cytokine treatments(6-7). Therefore, the model using INS-1E cells to mimic the 
physiologically relevant condition of the development of type-1 diabetes is 
well-established in literature. 
Next, I wanted to decide the optimal concentration of each cytokine in the cocktail. 
I first did a titration experiment to decide the optimal combination for IL-1beta (0 to 20 
ng/mL) and IFN-gamma (0 to 100 ng/mL). IL-1beta or IFN-gamma alone did not 
reduce the viability of INS-1E cells (Figure 2-2). This observation is consistent with 
previous studies showing that each individual cytokine does not induce apoptosis in 
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pancreatic beta cells, but rather they act synergistically to induce beta-cell 
apoptosis(8). The combination of both cytokines reduced the viability of INS-1E cells 
ranging from 65% to 85% of the untreated control. 
 
 
I decided to add the third pro-inflammatory cytokine, TNF-alpha, because these 
three cytokines are all detected in the pancreas during the development of type-1 
diabetes and are proven to cause beta-cell apoptosis. I then performed another 
titration to decide the optimal condition (Figure 2-3). The addition of TNF-alpha (25 
Figure 2-2. Titration experiment for 
IL-1beta and IFN-gamma. A titration 
experiment was performed using 
cellular ATP levels as a surrogate of 
viability. The relative ATP levels are 
normalized to untreated controls. Data 
are represented as the mean of 12 
independent wells. 
Figure 2-3. Titration 
experiment for IL-1beta, 
IFN-gamma and TNF-alpha. 
A titration experiment was 
performed using cellular ATP 
levels as a surrogate of 
viability. The relative ATP 
levels are normalized to 
untreated controls. Data are 
represented as the mean of 12 
independent wells. 
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ng/mL) further reduced the viability of INS-1E cells to 20% of the control. A higher 
dose TNF-alpha (50 ng/mL) does not lead to lower cell viability. It turns out that 
10ng/mL IL-1beta + 50ng/mL IFN-gamma + 25ng/mL TNF-alpha is the optimal 
cocktail for this readout. This cocktail reduces the cellular ATP levels by 2-fold after 
two-day treatment, while even higher concentrations of cytokines do not further 
reduce cellular ATP levels. 
 
Figure 2-4. Effects of cytokines in four different aspects of beta-cell biology. A) Cell 
viability assay; B) Caspase-3 assay; C) Mitochondrial membrane potential; D) Nitrite assay. 
Data are represented as the mean + standard deviation of 24 independent wells. 
This specific set of conditions was then used as a standard condition in future 
experiments. As a result, I was able to develop a high-throughput assay to measure 
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cellular ATP levels in 384-well plates (Figure 2-4 A). Other than the cellular ATP 
assay, I also developed three different high-throughput assays to measure caspase-3 
activity, mitochondrial membrane potential, and nitrite production. Caspase-3 is a 
downstream effector of the apoptotic pathway, and its activity is increased by a 
two-day exposure of INS-1E cells to the cytokine cocktail. Caspase-3 activity is 
measured by means of the luminometric Caspase Glo3/7 assay. After a two-day 
treatment of cytokine cocktail, caspase-3 activity is elevated by 6-fold compared to the 
no treatment condition (Figure 2-4 B). Cytokine-mediated beta-cell apoptosis has 
been reported to involve mitochondria, specifically through the loss of the 
mitochondrial membrane potential (∆Ψm). JC-1, a dye for the measurement of ∆Ψm, 
is initially green but forms red fluorescent aggregates in response to hyperpolarization, 
enabling a ratiometric calculation upon compound treatment(9). After a two-day 
treatment of cytokine cocktail, mitochondrial membrane potential is reduced by 40% 
compared to the no treatment condition (Figure 2-4 C). Nitric oxide will be measured 
colorimetrically by the nitrite accumulated in the cell-culture media, using the Griess 
reagent (a combination of naphthylenediamine dihydrochloride and sulphanilamide). 
IL-1beta is known to induce expression of the gene encoding iNOS, an effect that is 
potentiated by IFN-gamma. The subsequent formation of NO drives cell death by both 
necrosis and apoptosis. After a two-day treatment of cytokine cocktail, nitrite 
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production is elevated by 4-fold compared to the no-treatment condition (Figure 2-4 
D). 
Among the four assays developed to probe beta-cell biology, the ATP assay 
was chosen as the primary assay for HTS due to its robustness. A standard used to 
judge the robustness of a high-throughput assay is Z’ factor. The assay Z′ factor was 
calculated on the basis of the means and standard deviations of untreated and 
cytokine-treated wells (Equation 2-1) (10). An assay Z’ factor between 0.5 and 1 
means an excellent assay for HTS. The Z’ factor of the high-throughput assay to 
measure cellular ATP levels in INS-1E cells in 384-well plates is 0.5, which means the 
assay is ready for HTS. All three other assays are used as secondary assays to 
further characterize the performance of top positives in protecting beta cells from 
apoptosis. 
 
 
2.3 Pilot screen: results of a 2240-compound library 
I performed a pilot screen of 2,240 compounds to identify small-molecule 
suppressors of the cytokine cocktail on cellular ATP levels in INS-1E cells. These 
Equation 2-1. The equation for calculation Z’ factor. 
σp and σn are standard deviations for positive and 
negative control. µp and µn are means for positive and 
negative control. 
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seven 384-well plates included compounds from diverse sources such as known 
bioactives, natural products, commercial “drug-like” compounds, etc. and were 
screened in duplicate. The high reproducibility of both replicates further demonstrated 
the robustness of using this assay as the primary readout in the following HTS (Figure 
2-5). Compounds were considered “hits” if they increased ATP levels by 3 standard 
deviations relative to the mock-treatment (DMSO) distribution (Figure 2-6). Using this 
criterion, I identified 49 “hits”, including 21 bioactives, 9 compounds synthesized by 
diversity-oriented synthesis(11), 5 natural products, and 14 compounds from 
commercial vendors. Chemical similarity analysis of the 49 “hits” was performed in 
collaboration with Paul Clemons at the Broad Institute, and revealed four clusters 
containing similar compounds by inspection (Figure 2-7A). These clusters included 
two virtually identical compounds (alsterpaullone and kenpaullone), several pyrazole 
derivatives from commercial vendor libraries, nine compounds from diversity-oriented 
synthesis, and eight glucocorticoid derivatives (Figure 2-7). 
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 Figure 2-5. Scatter-plot results of the pilot screen. Each plate had been screened twice. 
Yellow dots are mock controls- wells treated with cytokine cocktails and DMSO. Blue dots are 
positive controls- wells treated with DMSO but without cytokine cocktails. Red dots represent 
different compounds. Axis is normalized to the average of positive controls (100% restoration) 
and mock controls (0% restoration). 
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 Figure 2-6. Evaluation of the screening results. Cellular ATP levels were assessed after 
treatment with each of 2,240 compounds. The signal change induced by compound treatment 
(“Δsignal”) represents the value for each compound normalized to mock-treated wells. The 
means and standard deviations of mock-treated (DMSO) wells and positive-control (no 
cytokine) wells are shown. Potential suppressors (shaded pink) were identified as those 
resulting in Δsignal three standard deviations above the DMSO distribution. 
 
Figure 2-7. Chemical similarity among screening “hits”. A) Forty-nine compounds  
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Fig. 2-7 (Continued)  
exceeding the “hit” threshold (c.f., Figure 2-6) were selected for cluster analysis (see Methods). 
Pairwise Tanimoto (T) similarity scores were computed among all compounds (heat map; T=0, 
black; T=1, white; linear grayscale), after which “hits” were clustered hierarchically 
(dendrogram). For groups with visually apparent similarities (four white/light blocks in heat 
map; blue bars at bottom), the maximum common substructure for each group is depicted. 
Structures of the compounds tested in this study: B) alsterpaullone, C) pyrazole derivatives, D) 
dexamethasone. 
 
2.4 Follow-up studies of GSK-3β  inhibitors, glucocorticoids, and pyrazoles in 
suppressing beta-cell apoptosis 
I decided to focus initially on a set of commercially available compounds. 
Alsterpaullone (12) (Figure 2-7 B), annotated as an inhibitor of both glycogen 
synthase kinase-3β (GSK-3β) and cyclin-dependent kinase 2/5 (CDK2/5), completely 
restored beta-cell ATP levels in a dose-dependent manner (Figure 2-8 A). Similarly, 
three pyrazole derivatives (Figure 2-7 C) increased ATP levels to >90% of untreated 
controls (Figure 2-8 B). Dexamethasone (Figure 2-7D), chosen as a representative 
glucocorticoid, was slightly less potent in enhancing ATP levels, to approximately 
80% of untreated levels (Figure 2-8 C). Caspase-3 is a downstream effector of the 
apoptotic pathway, and its activity is increased by a two-day exposure of INS-1E cells 
to the cytokine cocktail. This increase in activity was suppressed more than 50% by 1 
µM alsterpaullone (Figure 2-8 D). The pyrazole derivatives also reduced caspase-3 
activity in a dose-dependent manner (Figure 2-8 E), but dexamethasone was only 
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partially effective at reducing this activity. (Figure 2-8 F) These results indicate that 
screening for an increase in ATP levels can identify small molecules capable of 
halting the apoptotic process in the presence of inflammatory cytokines. However, 
secondary assays are still required to eliminate false positives. 
 
Figure 2-8. Suppression of cytokine-induced beta-cell damage. INS-1E cells were treated 
with cytokine cocktail in the presence of increasing concentrations of alsterpaullone (A,D), 
pyrazole derivatives (B, E), or dexamethasone (C, F), all expressed as micromolar 
concentrations. Cellular ATP levels (A, B, C) and caspase-3 activities (D, E, F) were measured 
and normalized to untreated controls. Data are represented as the mean ± standard deviation 
of 24 independent wells. *, p<0.01 relative to cytokine-treated cells. 
IL-1beta induces expression of inducible nitric oxide synthase (iNOS), an effect 
potentiated by IFN-gamma and TNF-alpha(13); the subsequent formation of NO 
drives β-cell death. Cellular production of nitrite, a stable oxidized product of NO used 
as a surrogate for NO levels, increased 3.5-fold after cytokine treatment and was 
completely inhibited by 2 µM alsterpaullone (Figure 2-9 A). The pyrazole derivatives 
were also effective in reducing nitrite production, though less so than alsterpaullone 
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(Figure 2-9 B). Interestingly, dexamethasone had no effect on cytokine-induced nitrite 
production (Figure 2-9 C). Finally, I examined the effects of these compounds on 
GSIS in INS-1E cells. Under normal conditions, stimulation with 15 mM glucose leads 
to a 3.6-fold increase in insulin secretion relative to low-glucose (2 mM) conditions 
(Figure 2-9 D). Cytokine treatment reduced GSIS to 1.4-fold. This loss of response 
was largely suppressed by the addition of 4 µM alsterpaullone to the cytokine cocktail, 
with stimulation elevated to 3.2-fold. Treatment with the pyrazole derivative 
SPB07503 resulted in 50% enhancement of GSIS, while dexamethasone had no 
effect. Together, these results suggest that cellular nitrite levels are correlated with 
GSIS in INS-1E cells; compounds that are capable of reducing nitrite production in the 
face of cytokine treatment also restore GSIS. 
 
Figure 2-9. Reduction of nitrite production correlates with restoration of  
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Fig. 2-9 (Continued) 
glucose-stimulated insulin secretion. Cellular nitrite production was measured after 
treatment with cytokine cocktail and increasing concentrations of A) alsterpaullone, B) 
pyrazole derivatives, or C) dexamethasone. Data represent the mean ± standard deviation of 
24 independent wells. D) Glucose-stimulated insulin secretion was measured in the presence 
of 2 mM glucose (white bars) and 15 mM glucose (gray bars) in the absence or presence of 
cytokines and alsterpaullone (4 µM), the pyrazole derivative SPB07503 (12 µM), or 
dexamethasone (10 µM). Data are represented as the mean ± standard deviation of 8 
independent wells. *, p<0.01 relative to cytokine-treated cells. 
 
Another GSK-3β inhibitor, Ro 31-8220, was, like alsterpaullone, among the 
top-scoring compounds. Although these kinase inhibitors likely interact with several 
targets, I reasoned that GSK-3β could be a relevant target accounting for the 
protective effect on β cells. Ro 31-8220 increased ATP levels, decreased caspase-3 
activity, and reduced cellular nitrite production (Figure 2-10 A,B,C). Similarly, the 
selective GSK-3β inhibitors lithium chloride(14) and CHIR99021(15) increased ATP 
levels in the presence of cytokines (Figure 2-10 D,G). However, lithium chloride 
completely abolished nitrite production, while CHIR99021 only decreased nitrite by 
20% (Figure 2-10 E,H). On the other hand, lithium cannot reduce caspase-3 activity 
but CHIR-99021 was able to decrease caspase-3 activity dose-dependently (Figure 
2-10 F,I). 
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 Figure 2-10. Suppression of cytokine-induced beta-cell damage by GSK-3β  kinase 
inhibitors. INS-1E cells were treated with cytokine cocktail in the presence of increasing 
concentrations of Ro 31-8220 (A, B, C), lithium chloride (D, E, F), or CHIR-99021 (G, H, I). 
Cellular ATP levels were assessed by luciferase-based luminescence (A, D, G) and 
normalized to untreated controls. Cellular nitrite production was determined using the Griess 
reagent (B, E, H) and represented as micromolar concentrations of nitrite. Caspase-3 activity 
was measured with a commercial kit (C, F, I) and normalized to the untreated controls. Data 
are represented as the mean ± standard deviation of 24 independent wells. 
 
To evaluate the specificity of these responses, I knocked down GSK-3β in 
INS-1E cells with small-interfering RNA (siRNA) constructs. Knock-down 
of GSK3B resulted in ATP levels that were 75% that of the mock-transfected control 
(Figure 2-11 A), in a complete reduction of caspase-3 activity, and in a 20% reduction 
in nitrite production (Figure 2-11 C). These results were similar to those achieved by 
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CHIR99021 and suggest that selective inhibition of GSK-3β is only partially protective 
of cytokine-treated INS-1E beta cells. 
 
Figure 2-11. Effects of genetic silencing of GSK-3β  on beta-cell viability. (A) Cellular 
ATP levels were determined in INS-1E treated with cytokine cocktail in the presence of mock 
transfection, scrambled siRNA, and GSK-3β-specific siRNA. Decreases in GSK-3β protein 
levels after siRNA transfection are shown by Western blot. (B) Caspase-3 activity and (C) 
cellular nitrite production under the same gene-silencing conditions. Data are represented as 
the mean ± standard deviation of 24 independent wells. 
 
2.5 Discussion and conclusion 
Inhibition of GSK-3β has been reported to protect beta cells against 
glucolipotoxicity and endoplasmic reticulum stress-induced β-cell death(16-17). There 
are key differences between these mechanisms and cytokine-induced apoptosis, so 
the fact that GSK-3β inhibitors could also suppress cytokine-induced β-cell apoptosis 
is not intuitively obvious. For example, the expression of iNOS and IκBα is 
upregulated by cytokines but not by high glucose concentrations(18-19). Further, fatty 
acids such as oleate and palmitate do not activate the NFκB pathway in either INS-1E 
or rat islets, and fatty acid-induced beta-cell death is independent of iNOS or nitrite 
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production(20). Because I observed a correlation between cellular nitrite production 
and GSIS, it is likely that inhibition of GSK-3β alone is insufficient to enhance beta-cell 
function lost due to inflammatory cytokines. These results suggest that alsterpaullone 
acts through multiple mechanisms, including GSK-3β inhibition, to protect beta cells 
from cytokine-induced apoptosis. 
Glucocorticoids are a class of steroid hormones that bind to nuclear hormone 
receptors, which in turn translocate to the nucleus and upregulate the expression of 
anti-inflammatory proteins(21). Although glucocorticoids are generally detrimental to 
β-cell development and insulin secretion(22), a recent study showed that high doses 
of dexamethasone increase beta-cell proliferation in rat islets(23). Here, I 
demonstrate that low-micromolar concentrations of dexamethasone increased cellular 
ATP levels and reduced caspase-3 activity in the presence of cytokines. However, 
dexamethasone neither reduced cytokine-induced nitrite production nor restored 
GSIS. These results indicate that glucocorticoids can only partially increase β -cell 
viability in this system. 
The novel pyrazole derivatives were obtained from commercially available 
libraries. I observed that these compounds protected cells against the detrimental 
effects of cytokines in all assays tested. To my knowledge, there have been no 
previous reports of the biological activities of these or related structures. These data 
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suggest that the pyrazole derivatives in this study could protect beta cells by an as-yet 
unknown mechanism. 
Because of the importance of pro-inflammatory cytokines to the beta cell, many 
efforts have been made to identify genetic or small-molecule approaches to protect 
beta cells from cytokine-induced death(3-4, 24-26). I have demonstrated the feasibility 
of cell-based screening to identify small molecules that prevent loss of β-cell viability 
in the presence of cytokines. I also find that reduction of cytokine-induced caspase 
activity and nitrite production appear to be prerequisites for enhancing physiological 
beta-cell function. The cytokines used here have numerous effects on beta cells, but I 
believe the use of this cocktail is a relatively fair model of the development of type-1 
diabetes. The suppressors identified here could be used as chemical probes to study 
beta-cell biology in the future. 
 
2.6 Methods and Materials 
Cell culture and reagents. INS-1E cells (generously provided by C. Wollheim and P. 
Maechler, University of Geneva) were maintained in RPMI 1640 containing 11 mM 
glucose, 10% fetal bovine serum, 10 mM HEPES, 50 µM 2-mercaptoethanol, 1 mM 
sodium pyruvate, cultivated at 37C with 5% CO2 in a humidified atmosphere, and split 
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every week. Recombinant rat IL-1β and recombinant mouse TNF-α were purchased 
from R&D Systems. Recombinant mouse IFN-γ, Griess reagent, and dexamethasone 
were purchased from Sigma. CellTiter-Glo and Caspase-Glo 3/7 reagents were 
purchased from Promega. Alsterpaullone and Ro 31-8220 were purchased from EMD 
Biosciences. The pyrazole derivatives were purchased from Maybridge. CHIR99021 
was synthesized as described (27) by Dr. Tim Lewis in Broad Institute. 
 
High-throughput screening for compounds affecting cellular ATP levels. INS-1E 
cells were seeded at 10,000 cells/well using a Multidrop Combi (Thermo Labsystems) 
in white optical 384-well plates (Corning Life Sciences). After overnight incubation, 
medium was removed and 50 µL RPMI containing 1% FBS and a combination of 
cytokines (10 ng mL-1 IL-1β, 50 ng mL-1 IFN-γ, 25 ng mL-1 TNF-α) was added to every 
well. Using libraries of compounds dissolved in DMSO and a CyBi-Well pin-transfer 
robot (CyBio Corp.), 0.1 µL of each compound was added. After 48 hr, medium was 
removed and 20 µL CellTiter-Glo reagent was added. Luminescence was measured 
after 10-min incubation using an EnVision plate reader (PerkinElmer). 
 
Screening data analysis. Instrument output files were processed using Pipeline Pilot 
(Accelrys) and input to MATLAB (The MathWorks) for data normalization. Compound 
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performance scores relative to a distribution of mock-treated (DMSO) wells were 
calculated using a revised version of the scoring system underlying ChemBank (28). 
The role of replicate treatments was further developed as follows: first, 
mock-treatment distributions were modeled using all mock-treated wells measured on 
a single day, regardless of their nominal replicate; second, per-compound scores 
weighted each in-plate background-subtracted measurement by the uncertainty in 
that measurement, using the method of maximum likelihood (29). The uncertainty in a 
single background-subtracted measurement was estimated using the number of 
mock-treated wells on the plate and, as a measure of the assay noise, the standard 
deviation of the per-day mock-treatment distribution. The signal, a weighted average 
of differences, was scaled by the noise, the standard deviation of the mock-treatment 
distribution. 
 
Chemical similarity analysis. Cluster analysis was performed using Pipeline Pilot 
extended connectivity fingerprints (unfolded ECFP_4s). Bits representing 
substructures present in more than 10%, and less than 90%, of the 49 compounds 
were selected to generate 96-bit representations for each structure. Pairwise 
Tanimoto (T) similarity scores were computed among all compounds, after which 
“hits” were clustered hierarchically (complete linkage), both using MATLAB. Maximum 
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common substructures for each group with similarities apparent by inspection were 
determined using Pipeline Pilot. 
 
Measurement of cellular nitrite production. INS-1E cells were seeded and treated 
as described for high-throughput screening. After treatment with cytokine and 
compounds for 48 hr, 10 µL modified Griess reagent (1:1 mixture of 1% sulfanilamide 
in 30% acetic acid and 0.1% N-(1-naphthyl) ethylenediamine dihydrochloride in 60% 
acetic acid) was added to each well. After 5-min incubation at room temperature, the 
absorbance at 540 nm was measured using an Envision plate reader. 
 
Caspase-3 activity assay. INS-1E cells were seeded at 5,000 cells/well in white 
optical 384-well plates and treated as described for high-throughput screening. After 
treatment with cytokines and compounds for 48 hr, medium was removed and 20 µL 
Caspase-Glo 3/7 reagent was added. Luminescence was measured after 2-hr 
incubation using an Envision plate reader. 
 
RNA interference and Western blotting. Small-interfering RNA against Gsk3b was 
obtained from Dharmacon. siRNAs (100 nM) were transfected into INS-1E cells 
(5,000 cells/well in a 384-well plate) using DharmaFECT reagent. Transfected cells 
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were cultured for 72hr, then collected for Western blot analysis and cell-based assays. 
For Western blotting, cells were lysed in RIPA buffer. Total protein was separated by 
4-12% SDS-PAGE and transferred to a PVDF membrane. Blots were developed 
using the chemiluminescence detection system SuperSignal (Thermo Fisher 
Scientific) and light emission was captured using an Imaging Station 4000MM 
(Carestream). 
 
Glucose-stimulated insulin secretion. INS1-E cells were seeded in 96-well plates 
at 20,000 cells/well and incubated for 48 hr in 100 µL fresh RPMI containing 1% FBS 
and the cytokine cocktail, in the presence or absence of compounds. Cells were 
washed and incubated for 2 hr in KRBH (135 mM NaCl, 3.6 mM KCl, 5 mM NaHCO3, 
0.5 mM NaH2PO4, 0.5 mM MgCl2, 1.5 mM CaCl2, 10 mM HEPES, pH 7.4, 0.1% BSA) 
buffer without glucose. Cells were subsequently incubated with KRBH buffer 
containing 2 mM or 15 mM glucose for 1 hr. The supernatant was taken for 
measurement of released insulin, and 100 µL acidified ethanol added to each well for 
extraction and measurement of cellular insulin content. Insulin was measured with a 
rat insulin ELISA kit (Alpco). 
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Chapter 3: Identification of HDAC3 as a target for suppressing 
cytokine-induced beta-cell apoptosis 
3.1 Introduction 
Protein acetylation has emerged as an important post-translational modification 
that regulates multiple cellular functions, including chromatin remodeling and 
transcriptional regulation(1-2), microtubule dynamics and intracellular transport(3-4), 
metabolism, and ageing(5). Histone deacetylases (HDACs) and histone 
acetyltransferases (HATs) regulate these processes by modulating the lysine 
acetylation of proteins. Much research has focused on the acetylation of histones — 
major components of chromatin — owing to the important roles these proteins have in 
vital cellular functions and in disease(6-7). Levels of histone acetylation depend on 
the activities of HATs and HDACs, which add or remove acetyl groups from protein 
substrates, respectively. In general, an increase in histone acetylation causes 
remodeling of chromatin from a tightly packed configuration to a loosely packed 
configuration, which subsequently leads to transcriptional activation. Conversely, a 
decrease in histone acetylation may cause chromatin structure to condense and 
result in transcriptional silencing. Therefore, upregulation of transcription can be 
achieved in cells either by stimulation of HAT or by inhibition of HDAC activities 
Traditionally, HDACs have been classified based on the molecular analysis of 
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protein structure and their homology to yeast enzymes(8). Class I (HDAC1, HDAC2, 
HDAC3 and HDAC8), class IIa (HDAC4, HDAC5, HDAC7 and HDAC9), class IIb 
(HDAC6 and HDAC10) and class IV (HDAC11) HDACs contain zinc-dependent 
deacetylase domains. The class III HDACs (sirtuins, SIRT1–SIRT7) belong to a 
distinct class of NAD+-dependent hydrolases. Class I and class II HDACs share 
significant structural homology, especially within the highly conserved catalytic 
domains. HDAC1 was the first HDAC to be identified and characterized. HDAC1 was 
isolated by affinity chromatography with a derivative of a natural product, trapoxin A, 
which was discovered in a phenotypic screen involving the change in the spindle-like 
morphology of v-sis-transformed NIH 3T3 cells to the flattened morphology 
of fibroblasts(9). Subsequently, trapoxin A was shown to inhibit the histone 
deacetylase activity(10-11). By affinity chromatography, trapoxin A was found to bind 
to a previously unidentified protein, HDAC1(12). This discovery of HDAC1 opened up 
many investigations of histone deacetylase function and quickly led to the observation 
that HDACs both deacetylate histones in vitro and silence gene expression in 
vivo(12-13). 
In the past decade, a number of HDAC inhibitors were developed as tool 
compounds for studying chromatin biology and clinical candidates of cancer(14). 
Crystallographic study using HDAC inhibitors, trichostatin A (TsA) and 
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suberoylanilide hydroxamic acid (SAHA), indicates that these compounds inhibit 
HDAC activity by interacting with the catalytic site of HDACs(15). Recently, a study 
demonstrated that erstwhile pan-HDAC inhibitors possess different isoform selectivity 
based on their activities in biochemical assays(16). For example, suberoylanilide 
hydroxamic acid (SAHA) inhibits the activities of HDAC1, 2, 3, 6, and 8, while MS-275 
only inhibits the activities of HDAC1, 2, and 3. Therefore, structurally diverse HDAC 
inhibitors may have different cellular effects because of different isoform selectivity. 
Intensive therapeutic development efforts have focused on small-molecule HDAC 
inhibitors. Initially, this interest was precipitated by the discovery of the anticancer 
potential of HDAC inhibitors(17). Subsequently, potential therapeutic applications 
were broadened to include other human illnesses, including CNS diseases(18) and 
cystic fibrosis(19). Therefore, although cancer remains a primary target for 
HDAC-based therapy, significant efforts have been made to develop compounds, 
especially isoform-selective inhibitors, for the treatment of numerous diseases. 
Recently, an important role for histone deacetylases (HDACs) in suppressing 
beta-cell apoptosis was suggested, perhaps by decreasing NFκB transactivation 
(reviewed in (20)). Larsen et al. demonstrated that the HDAC inhibitors SAHA and 
trichostatin A (TsA) partially prevented cytokine-induced beta-cell toxicity (21). 
However, neither SAHA nor TsA could restore GSIS. ITF2357, another 
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broad-spectrum HDAC inhibitor, had in vivo activity, protecting mouse islets from 
cytokines and preventing hyperglycemia in streptozocin-treated mice (22). 
In this chapter, I investigated a structurally diverse panel of HDAC inhibitors for 
their cellular effects in cytokine-induced beta-cell apoptosis. I demonstrate that 
MS-275, an inhibitor specific for HDAC1, 2, and 3, prevents beta-cell apoptosis and 
restores GSIS to a greater extent than more promiscuous HDAC inhibitors, such as 
SAHA. I further show that specific inhibition of HDAC3 is responsible for the protective 
effects of MS-275. 
 
3.2 MS-275 and CI-994 are better suppressors than SAHA and TsA in 
suppressing beta-cell apoptosis 
Using cellular ATP levels as a surrogate for cell viability (23), I tested the effects 
of eleven structurally diverse HDAC inhibitors (Figure 3-1) in protecting the rat INS-1E 
insulinoma cell line (24) from cytokine-induced apoptosis. Most of these compounds 
restored ATP levels to varying degrees (Figure 3-2 A). However, we observed very 
different effects on caspase-3 activity after compound treatment. MS-275 and CI-994 
were the only two compounds that reduced caspase-3 activity significantly, while 
other HDAC inhibitors either were inactive or, like PXD101 and SAHA, even increased 
caspase-3 activity (Figure 3-2 B). Most compounds decreased nitrite secretion, a 
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surrogate for nitric oxide production, but the effects were more moderate (Figure 3-2 
C). When I performed hierarchical clustering (Figure 3-2 D), the compounds with the 
most beneficial effects on cytokine-treated beta cells clustered together, and in 
particular were those that selectively inhibited the activities of HDAC1, 2, and 3 
(MS-275 and CI-994) (Figure 3-2 A,B). These results suggest that only certain HDAC 
isoforms are important to cytokine-induced beta-cell apoptosis, and that the selectivity 
of HDAC inhibitors is an important consideration in assessing this activity. 
 
Figure 3- 1. Structures of HDAC inhibitors used in this study. Concentrations used were: 
APHA, 5 µM; pyroxamide, 5 µM; TsA, 0.05 µM; SAHA, 1 µM; apicidin, 0.05 µM; 3, 5 µM; 
CI-994, 10 µM; LAQ824, 1 µM; PXD101, 0.2 µM; MS-275, 5 µM; Scriptaid, 1 µM. 
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 Figure 3-2. Phenotypic profiling of eleven HDAC inhibitors in beta cells. Eleven HDAC 
inhibitors were tested for activity in the presence of a cocktail of inflammatory cytokines in rat 
INS-1E cells for (A) cellular ATP levels, (B) caspase-3 activity and (C) nitrite production. (D) 
Results from (A), (B) and (C) was displayed into heat map. Activity was normalized to a range 
of -1 (green), decrease in signal relative to the untreated condition (“NT”), to 1 (red), increase 
in signal relative to the untreated condition. (E) The chemical structures of HDAC inhibitors 
studied in more detail: 1 (MS-275), 2 (SAHA), 3, and 4 (CI-994). 
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Figure 3-3. Cellular ATP levels of INS-1E cells treated with 11 different HDAC inhibitors in the 
absence of the cytokine cocktail were used to determine the maximum concentration of each 
compound used in the follow-up assays. 
 
These measurements were made at a single compound concentration, the 
highest at which the cells remained viable (Figure 3-3). In order to determine 
concentration dependence, we tested MS-275 and SAHA as exemplars of class I 
(HDAC1, 2, 3) and broad-spectrum inhibition, respectively, over a 4- to 5-fold range of 
concentrations. Both MS-275 and SAHA restored ATP levels in INS-1E cells treated 
with cytokines, with SAHA resulting in a greater suppression (Figure 3-4 A). However, 
SAHA slightly increased caspase-3 activity, while MS-275 reduced caspase-3 activity 
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in the presence of cytokines by approximately 50% (Figure 3-4 B). MS-275 and SAHA 
resulted in comparable reduction of nitrite production in the presence of cytokines 
(Figure 3-4 C). Consistent with previous reports that SAHA could not restore the 
impairment in GSIS caused by treatment with cytokines (21), we confirmed that 1 µM 
SAHA had no effect on GSIS, while 5 µM MS-275 restored GSIS in the presence of 
cytokines (Figure 3-4 D). Moreover, MS-275 was also more effective in restoring 
mitochondrial membrane potential, another readout of apoptosis, than SAHA (Figure 
3-5). These results suggest that MS-275 may be a superior suppressor of 
cytokine-induced beta-cell apoptosis than less selective HDAC inhibitors. 
 
 
Figure 3-4. Cytokine-induced 
apoptosis is suppressed by 
MS-275 but not SAHA. (A) Effects 
of MS-275 and SAHA on cellular ATP 
levels in INS-1E cells after 48 hours 
in the presence of the cytokine 
cocktail. (B) Effects of MS-275 and 
SAHA on caspase-3 activity after 
48-h treatment. (C) Effects of 
MS-275 and SAHA on the cellular 
production of nitrite after 48-h 
treatment. (D) Effects of MS-275 and 
SAHA on glucose-stimulated insulin 
secretion after 48-h treatment. Data 
represent the mean ± standard 
deviation of 8 independent wells for 
insulin secretion and 24 independent 
wells for others. * indicates p < 0.01 
as compared to the cytokine 
treatment alone. 
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3.3 siRNA-based knock-down studies identified HDAC3 as a target for 
suppressing of cytokine-induced beta-cell apoptosis 
I then sought to determine the HDAC isoform(s) responsible for suppression of 
cytokine-induced beta-cell apoptosis. MS-275 is a selective inhibitor of HDAC1, 2, 
and 3, while SAHA additionally inhibits HDAC6 and 8(16). I reasoned that inhibition of 
HDAC1, 2, or 3 led to the protective effects of MS-275. To test this hypothesis, I 
performed gene-silencing experiments targeting these HDACs using small-interfering 
RNA (siRNA). siRNA duplexes specific for Hdac1, Hdac2, or Hdac3 were transfected 
into INS-1E cells, leading to a selective decrease in protein expression of the 
appropriate HDAC (Figure 3-6). Each knock-down alone had no effect on viability 
(Figure 3-7).  
Figure 3-5. Effects of MS-275 
and SAHA on restoring 
mitochondrial membrane 
potential (ΔΨm) in the presence 
of cytokines. Data represent the 
mean ± standard deviation of 24 
independent wells. * indicates p < 
0.01 as compared to the cytokine 
treatment alone. 
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Knock-down of Hdac2 or Hdac3 in the presence of cytokines each resulted in a 
35% restoration of ATP levels, while knock-down of Hdac1 had no effect (Figures 3-8 
A). Only knock-down of Hdac3 was sufficient to reduce caspase-3 activity (Figure 3-8 
B). The protective effect of Hdac3 knock-down is verified using two different siRNA 
constructs (Figure 3-9). Knock-down of either Hdac2 or Hdac3 resulted in slight but 
statistically significant reduction in nitrite production (Figure 3-8 C), while again 
knock-down of Hdac1 had no effect. We observed similar effects of genetic 
knock-downs using a cell death ELISA readout measuring DNA-histone complexes 
(Figure 3-10). Importantly, knock-down of Hdac3 alone led to restoration of GSIS 
(Figure 3-8 D), showing that the beta cells are fully functional. Moreover, knock-down 
of either Hdac2 or Hdac3 resulted in restoration in mitochondrial membrane potential 
(Figure 3-11). These results indicate that inhibition of HDAC3 is responsible for the 
Figure 3-6. A) Western blots 
validating the specificity of each 
siRNA construct in knocking-down 
a single HDAC isoform. B) 
Quantification of Western blots 
shown in (A). 
 
Figure 3-7. Knock-down of 
individual HDAC isoform in the 
absence of cytokine cocktails had 
no effects on cellular ATP levels. 
Data represent the mean ± 
standard deviation of 24 
independent wells. 
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protective effects of MS-275 on beta cells in the presence of inflammatory cytokines. 
Further, insulin secretion does not appear to be correlated with ATP levels alone, but 
rather is more related to caspase activity. 
 
Figure 3-8. Genetic knock-down of Hdac3 suppresses beta-cell apoptosis. The effects of 
knocking down Hdac1, 2, or 3 on (A) cellular ATP levels, (B) caspase-3 activity, (C) nitrite 
production, or (D) glucose-stimulated insulin secretion. Data represent the mean ± standard 
deviation of 8 independent wells for insulin secretion and 24 independent wells for others. * 
indicates p < 0.01 as compared to the cytokine treatment alone. 
 
Figure 3-9. Two independent siRNA constructs of rat Hdac3 restored cellular ATP levels and 
reduced caspase-3 activity in the presence of the cytokine cocktail. Data represent the mean ± 
standard deviation of 24 independent wells. 
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3.4 Further evidence from small-molecule HDAC inhibitors (“Merck 60” and 
HDAC3-seletive inhibitors) 
To further demonstrate the importance of HDAC3 in protecting insulin-secreting 
cells from cytokine-induced apoptosis, I used small-molecule inhibitors to chemically 
isolate HDAC3 activity. CI-994, an inhibitor selective for HDAC1, 2, and 3, restored 
ATP levels and reduced caspase-3 activity in INS-1E cells (Figure 3-12 A, B). A 
2-thiophenyl analog of CI-994, 3 (Figure 3-2 E), exhibits inhibitory activity toward 
HDAC1 and 2 only (IC50 7 and 49 nM, respectively, vs. 10 µM for HDAC3) (25). Thus, 
I could indirectly assess the effects of HDAC3 inhibition by comparing the activities of 
Figure 3-11. Effects of knocking down 
each HDAC isoform on restoring 
mitochondrial membrane potential (ΔΨm) 
in the presence of cytokines. Data 
represent the mean ± standard deviation 
of 24 independent wells. 
Figure 3-10. Effects of knocking down 
each HDAC isoform on reducing 
DNA-histone complexes released from 
the nucleus to the cytoplasm in the 
presence of cytokines. Data represent the 
mean ± standard deviation of 4 
independent wells. Data were normalized 
to the cytokine-treated, scrambled siRNA 
condition (100%). 
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3 and CI-994. Although 3 restored ATP levels (Figure 3-12 A), it did not reduce 
caspase-3 activity (Figure 3-12 B). Mitochondrial membrane potential was completely 
restored by CI-994, but not by 3 (Figure 3-13). These results further demonstrate the 
crucial role of HDAC3 in cytokine-induced beta-cell apoptosis. 
 
Figure 3-12. Analysis of chemical HDAC3 inhibition on beta-cell apoptosis. Effects of 3 
and 4 (CI-994) on (A) cellular ATP levels and (B) caspase-3 activity in the presence of 
cytokines. Data represent the mean ± standard deviation of 24 independent wells. * indicates p 
< 0.01 as compared to the cytokine treatment alone. 
 
I also tested some HDAC inhibitors that show selectivity toward HDAC3, but not 
HDAC1 and HDAC2. These compounds were synthesized by Professor Jacob 
Figure 3-13. Effects of 3 and CI-994 on 
restoring mitochondrial membrane potential 
(ΔΨm) in the presence of cytokines. Data 
represent the mean ± standard deviation of 
24 independent wells. * indicates p < 0.01 
as compared to the cytokine treatment 
alone. 
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Hooker at Massachusetts General Hospital (Figure 3-14), originally as part of an effort 
to identify potential in vivo imaging agents for HDAC activity. Compound 5-9 are 
HDAC inhibitors that show selectivity toward HDAC3. However, compound 10, like 3, 
has an aromatic substituent in the biasing element and is selective toward HDAC1 
and HDAC2. 
 
Figure 3-14. HDAC inhibitors synthesized by Prof. Jacob Hooker, a collaborator at MGH. 
Biochemical assay was done using caliper assay (Caliper Life Sciences). 
In measuring cellular ATP levels in the presence of cytokines, I found that all the 
compounds were able to restore cell viability in the presence of cytokines (Figure 
3-15). This result is consistent with the result of CI-994 and compound 3. However, 
only compounds 5-9 were able to reduce caspase-3 activity by 40% in the presence of 
cytokines (Figure 3-16). Compound 10 cannot reduce caspase-3 activity. Here, the 
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results from small-molecule HDAC3-selective inhibitors further show the important 
role of HDAC3 in cytokine-induced beta-cell apoptosis. 
 
 
 
3.5 Conclusion 
In conclusion, I evaluated a panel of eleven clinically advanced HDAC inhibitors 
and found that MS-275 and CI-994 suppress cytokine-induced beta-cell apoptosis, 
while the less selective inhibitors SAHA and TsA do not. By comparing these results 
to biochemical activities, I narrowed down the possible HDAC targets to a 
combination of HDAC1, 2, or 3. Using siRNA reagents and isoform-selective inhibitors, 
I observed that inhibition of HDAC3 appears to be critical for the protective effects of 
Figure 3-15. Analysis of small-molecule 
HDAC3 inhibition on beta-cell apoptosis. 
Effects of 5 to 10 were tested in cellular ATP 
levels. Concentrations used were: 5, 2.5 µM 
and 5 µM; 6, 5 µM and 10 µM; 7, 5 µM and 10 
µM; 8, 5 µM and 10 µM; 9, 5 µM and 10 µM; 
10, 5 µM and 10 µM. 
Figure 3-16. Analysis of small-molecule 
HDAC3 inhibition on beta-cell apoptosis. 
Effects of 5 to 10 were tested in caspase-3 
activity. Concentrations used were: 5, 2.5 µM 
and 5 µM; 6, 5 µM and 10 µM; 7, 5 µM and 10 
µM; 8, 5 µM and 10 µM; 9, 5 µM and 10 µM; 
10, 5 µM and 10 µM. 
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HDAC inhibitors, while the inhibition of additional isoforms may be deleterious to 
beta-cell function. The lack of correlation between ATP levels and caspase activity 
after treatment with some of these compounds suggests that these assays are 
reading out different aspects of cell toxicity. This notion is consistent with a previous 
analysis of the lack of overlap between viability assay readouts in hepatoma cells (26). 
Larsen et al. demonstrated that inhibition of the NFκB pathway is responsible for the 
protective effects of HDAC inhibitors. The p65 subunit of NFκB is acetylated by both 
p300 and PCAF on lysines 122 and 123(27). Acetylated p65 is subsequently 
deacetylated through a specific interaction with HDAC3(28). Acetylation of p65 
reduces its ability to bind κΒ-DNA(27). Moreover, acetylation of p65 facilitated its 
removal from DNA and consequently its IκΒα-mediated export from the nucleus(27). 
Therefore, inhibition of HDAC3 could reduce the activity of NFκB. This is totally 
consistent with my finding that selective inhibition of HDAC3 is responsible for 
preventing cytokine-induced beta-cell apoptosis. This study suggests the 
development of more selective HDAC3 inhibitors, and exploration of their potential 
uses in protecting pancreatic beta cells from inflammatory attack during the 
development of type-1 diabetes. 
 
3.6 Methods and Materials 
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Cell culture and reagents. INS-1E cells (generously provided by Claes Wollheim 
and Pierre Maechler, University of Geneva, Switzerland) were maintained in culture 
medium (RPMI 1640 containing 11 mM glucose, 10% fetal bovine serum, 10 mM 
HEPES, 50 µM 2-mercaptoethanol, 1 mM sodium pyruvate) and cultivated at 37C 
with 5% CO2 in a humidified atmosphere. Recombinant rat IL-1β and recombinant 
mouse TNF-α were purchased from R&D Systems. Recombinant mouse IFN-γ and 
Griess reagent were purchased from Sigma. CellTiter-Glo and Caspase-Glo 3/7 
reagents were purchased from Promega. Rabbit antibodies for HDAC1, 2 and 3 were 
from CellSignaling. Mouse monoclonal antibody to tubulin was from Sigma. 
Secondary horseradish peroxidase-conjugated goat anti-mouse and anti-rabbit 
antibodies were from Thermo Fisher Scientific. HDAC inhibitors were purchased from 
Sigma or synthesized in-house. 
 
Measurement of cellular ATP levels. INS-1E cells were seeded at 10,000 cells/well 
using a Multidrop Combi (Thermo Labsystems) in white optical 384-well plates 
(Corning Life Sciences). After overnight incubation, medium was removed and 50 µL 
RPMI containing the treated compound, 1% FBS and a combination of cytokines (10 
ng/mL IL-1β, 50 ng/mL IFN-γ, 25 ng/mL TNF-α) was added to every well. After 
incubation for 48 hr, medium was removed and 20 µL CellTiter-Glo reagent was 
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added. Luminescence was measured after 10-min incubation using an EnVision plate 
reader (PerkinElmer). 
 
Measurement of cellular nitrite production. INS-1E cells were seeded at 10,000 
cells/well using a Multidrop Combi (Thermo Labsystems) in white optical 384-well 
plates (Corning Life Sciences). After overnight incubation, medium was removed and 
50 µL RPMI containing the treated compound, 1% FBS and a combination of 
cytokines (10 ng/mL IL-1β, 50 ng/mL IFN-γ, 25 ng/mL TNF-α) was added to every well. 
After treatment with cytokine and compounds for 48 hr, 10 µL modified Griess reagent 
(1:1 mixture of 1% sulfanilamide in 30% acetic acid and 0.1% N-(1-naphthyl) 
ethylenediamine dihydrochloride in 60% acetic acid) was added to each well. After 
5-min incubation at room temperature, the absorbance at 540 nm was measured 
using an Envision plate reader (PerkinElmer). 
 
Measurement of mitochondrial membrane potential. INS-1E cells were seeded at 
10,000 cells/well using a Multidrop Combi (Thermo Labsystems) in white optical 
384-well plates (Corning Life Sciences). After overnight incubation, medium was 
removed and 50 µL RPMI containing the treated compound, 1% FBS and a 
combination of cytokines (10 ng/mL IL-1β, 50 ng/mL IFN-γ, 25 ng/mL TNF-α) was 
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added to every well. After treatment with cytokine and compounds for 48 hr, 20 µL of 
3.25µM JC-1 was added to each well. After 3hr incubation at 37°C, the cells were 
gently washed three times with 50 µL per well of 1X PBS (with Ca2+ and Mg2+). 
Fluorescence was measured with an EnVision plate reader (PerkinElmer) at the 
rhodamine spectra (excitation/emission 530 nm/580 nm) followed by fluorescein 
(excitation/emission 485 nm/530 nm). The ratio of rhodamine to fluorescein intensity 
was determined and represents the degree of mitochondrial membrane potential. 
 
Caspase-3 activity assay. INS-1E cells were seeded at 5,000 cells/well using a 
Multidrop Combi (Thermo Labsystems) in white optical 384-well plates (Corning Life 
Sciences). After overnight incubation, medium was removed and 50 µL RPMI 
containing the treated compound, 1% FBS and a combination of cytokines (10 ng/mL 
IL-1β, 50 ng/mL IFN-γ, 25 ng/mL TNF-α) was added to every well. After treatment with 
cytokines and compounds for 48 hr, medium was removed and 20 µL Caspase-Glo 
3/7 reagent was added. Luminescence was measured after 2-hr incubation using an 
Envision plate reader (PerkinElmer). 
 
Measurement of cellular apoptosis. INS-1E cells were seeded at 10,000 cells/well 
using a Multidrop Combi (Thermo Labsystems) in white optical 384-well plates 
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(Corning Life Sciences). After overnight incubation, medium was removed and 50 µL 
RPMI containing the treated compound, 1% FBS and a combination of cytokines (10 
ng/mL IL-1β, 50 ng/mL IFN-γ, 25 ng/mL TNF-α) was added to every well for a 
48hr-treatment. The degree of cytokine-induced apoptosis was determined by 
cell-death detection ELISA (Roche) measuring the amount of DNA-histone complexes 
present in the cytoplasmic lysates according to manufacturer’s description. This assay 
is based on a sensitive fluorescent nucleic acid stain facilitating the quantification of 
double-stranded DNA in solution. 
 
RNA interference and Western blotting. Small-interfering RNAs against Hdac1, 2 
and 3 were obtained from Dharmacon. siRNAs (100 nM) were transfected into INS-1E 
cells (5,000 cells/well in a 384-well plate) using DharmaFECT reagent. Transfected 
cells were cultured for 72hr, then collected for Western blot analysis and cell-based 
assays. For Western blotting, cells were lysed in RIPA buffer. Total protein was 
separated by 4-12% SDS-PAGE and transferred to a PVDF membrane. Blots were 
developed using the chemiluminescence detection system SuperSignal (Thermo 
Fisher Scientific) and light emission was captured using an Imaging Station 4000MM 
(Carestream). 
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Glucose-stimulated insulin secretion. INS-1E cells were seeded in 96-well plates 
at 20,000 cells/well in 100 µL RPMI and incubated for 48 hr in 100 µL fresh RPMI 
containing 1% FBS and the cytokine cocktail in the presence or absence of 5 µM 
MS-275. Cells were washed and incubated for 2 hr in KRBH buffer (135 mM NaCl, 3.6 
mM KCl, 5 mM NaHCO3, 0.5 mM NaH2PO4, 0.5 mM MgCl2, 1.5 mM CaCl2, 10 mM 
HEPES, pH 7.4, 0.1% BSA) lacking glucose. Cells were subsequently incubated with 
KRBH buffer containing 2 mM or 16 mM glucose for 1 hr. The supernatant was 
collected for measurement of secreted insulin. Insulin was measured with a rat insulin 
ELISA kit (Alpco). 
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Chapter 4: Identification of BRD0476 as a novel suppressor of 
cytokine-induced beta-cell apoptosis 
4.1 Introduction 
Type-1 diabetes is caused by the autoimmune destruction of insulin-producing 
beta cells in the pancreas. The infiltration of pancreatic islets by macrophages and 
secretion of inflammatory cytokines such as IL-1β, IFN-γ, and TNF-α are believed to 
cause beta-cell death(1). Activation of transcription factors such as NFκB and STAT1 
by these cytokines triggers the intrinsic apoptotic pathway in both rodent and human 
cell models(2). A small-molecule probe capable of preventing or reversing 
cytokine-induced beta-cell death could have great potential in developing therapies 
for early-stage type-1 diabetes. 
Previous efforts to suppress beta-cell apoptosis with small molecules involved 
compounds with antioxidant or antiinflammatory activity(3-4), and more recently with 
inhibitors of histone deacetylase activity(5-6). In chapter 2, I described a suite of 
cell-based assays that can be used to identify small-molecule suppressors of beta-cell 
death, and examined the effects of inhibitors of glycogen synthase kinase 3β, 
pyrazole derivatives, and glucocorticoids(7). This pilot-scale screen identified small 
molecules that increased ATP levels, but the majority of these compounds did not 
have effects on other aspects of beta-cell biology, such as insulin secretion. Therefore, 
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I sought to identify more complete suppressors of cytokine-induced beta-cell 
apoptosis that result in normal beta-cell function. 
In this chapter, I will describe a large-scale high-throughput screen (HTS) effort to 
identify suppressors of cytokine-induced beta-cell apoptosis. I screened 29,760 
compounds and identified several hit compounds. Among them, BRD0608, a 
compound synthesized via diversity-oriented synthesis (DOS)(8-10), was chosen for 
follow-up studies. I will also describe the development of a stereochemically diverse 
library of medium-sized rings, which led to the synthesis of BRD0608. Further 
optimization of the initial hit cluster and follow-up biological studies resulted in a 
compound, BRD0476, capable of restoring physiological properties to beta cells in the 
presence of these cytokines. 
 
4.2 Results of a 29,760-compound library screen 
As described in Chapter 2, I developed a high-throughput assay using INS-1E 
cells to screen for suppressors of cytokine-induced beta-cell apoptosis(7). I 
collaborated with Dr. Patrick Faloon in the Chemical Biology Platform of Broad 
Institute to screen a 29,760-compound library. Dr. Faloon provided guidance in using 
screening instruments and analyzing screening data. In the screen, the rat beta cell 
line INS-1E(11) was treated in 384-well format with this library in the presence of a 
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cocktail of inflammatory cytokines (IL-1β, IFN-γ, and TNF-α) for 48 hours. 
Luciferase-based measurement of cellular ATP levels was used as a surrogate of cell 
viability. In the primary high-throughput screen (HTS), compounds were called active 
if they increased cellular ATP levels, indicated by an increase in luminescence. The 
positive control, the pyrazole SPB07503 (Figure 2-7), increased ATP levels at 10 µM, 
and was used to normalize data. For the primary screen and other assays, 
negative-control (NC) wells and positive-control (PC) wells were included on every 
plate. Compounds with activities >3 standard deviation of NC were considered hits 
and chosen for confirmation in dose studies. The raw signals of the plate wells were 
normalized using the software Genedata Assay Analyzer (v7.0.3). The median raw 
signal of the intra-plate NC wells was set to a normalized activity value of 0, while the 
median raw signal of the intra-plate PC wells was set to a normalized activity value of 
100. Experimental wells were scaled to this range, resulting in an activity score 
representing the percent change in signal relative to the intra-plate controls. In total, 
29,760 compounds were screened in duplicate and the two replicates correlated well 
since most of the points were near the diagonal (Figure 4-1). 
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Figure 4-2. Critical path for high-throughput screen. 29,760 compounds were screened in 
HTS. Among them, 294 were chosen for further 8-dose retest confirmation. 54 out of 294 were 
Figure 4-1. Scatter-plot of 
the HTS result. Each plate 
was screened twice. Yellow 
dots are mock controls- wells 
treated with cytokine cocktails 
and DMSO. Blue dots are 
positive controls. Red dots 
represent different compounds. 
Axis is normalized to the 
average of positive controls 
(100% restoration) and mock 
controls (0% restoration). 
71
Fig. 4-2 (Continued) 
confirmed to increase cellular ATP levels in a dose-dependent manner. These 54 compounds 
were further tested in secondary assays including caspase-3 activity, mitochondrial membrane 
potential, nitrite production and glucose-stimulated insulin secretion (GSIS). In the end, one 
compound was prioritized for human islets studies. 
 
After the primary screen, I chose 294 compounds for further 8-dose retest 
confirmation (Figure 4-2). The 294 compounds included active compounds selected 
from the primary screen, and their structurally similar analogs. 42 out of the 294 are 
compounds with activities >3 standard deviation of NC. Other active compounds were 
picked using several other analysis methods. The results of the 294 compounds were 
then used to evaluate different analysis methods. Analogs were only chosen for 
chemical similarity without the consideration of any cellular activity. 54 out of 294 were 
confirmed to increase cellular ATP levels in a dose-dependent manner with an EC50 
value in Genedata Assay Analyzer. These 54 compounds were further tested in 
secondary assays, including caspase-3 activity, mitochondrial membrane potential, 
nitrite production, and glucose-stimulated insulin secretion (GSIS). A suppressor of 
beta-cell apoptosis should be able to reduce caspase-3 activity in the presence of 
cytokines. However, most compounds fell out of consideration after running the 
caspase-3 assay. For example, 17-allylamino-17-demethoxygeldanamycin 
(17-AAG), an analog of geldanamycin, increased cellular ATP levels to 150% of the 
positive control in the presence of the cytokine cocktail (Figure 4-3 A). However, it not 
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only could not reduce caspase-3 activity, but further increased its activity by nearly 
50% (Figure 4-3 B). 17-AAG, an Hsp90 inhibitor, is a less toxic and more stable 
analog of geldanamycin(12). 17-AAG induces the degradation of proteins that are 
mutated in tumor cells such as v-src, bcr-abl and p53 preferentially over their normal 
cellular counterparts by inhibiting Hsp90(13). Therefore, it is not surprising that 
17-AAG can increase caspase-3 activity, an apoptosis marker, since it could also 
induce apoptosis in cancer cells. 
 
Figure 4-3. Effects of 17-AAG in dose studies. 17-AAG was tested in 8 does in duplicate 
(circles and triangles are two independent experiments) for A) cellular ATP levels and B) 
caspase-3 activity. The median raw signal of the intra-plate NC wells was set to a normalized 
activity value of 0, while the median raw signal of the intra-plate PC wells was set to a 
normalized activity value of 100. C) Chemical structure of 17-AAG, an analog of 
geldanamycin. 
 
There were also compounds that had the desired protective effects. 
Hemanthamine is a crinine-type alkaloid natural product. The crinine-type alkaloids, 
which have the 5,10b-ethanophenanthridine skeleton as the core structure, 
represented by hemanthidine, pretazettine, and tazettine, have received considerable 
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attention, since they have been reported to possess antiviral, anticancer, and other 
interesting activities(14-16). Hemanthamine restored cellular ATP levels to ~60% of 
the positive control (Figure 4-4 A) and slightly reduced caspase-3 activity (Figure 4-4 
B). However, owing to the lack of commercial availability and to the difficulty of 
synthesizing this alkaloid, I decided not to pursue hemanthamine in further follow-up 
studies. 
 
Figure 4-4. Effects of hemanthamine in dose studies. Hemanthamine was tested in 8 does 
in duplicate (circles and triangles are two independent experiments) for A) cellular ATP levels 
and B) caspase-3 activity. The median raw signal of the intra-plate NC wells was set to a 
normalized activity value of 0, while the median raw signal of the intra-plate PC wells was set 
to a normalized activity value of 100. C) Chemical structure of hemanthamine. 
 
Another promising compound, 9-methylstreptimidone, was first isolated as an 
antibiotic(17) but later rediscovered from the culture filtrate of Streptomyces species 
by Umezawa and co-workers in 2006 as an inhibitor of NFκB pathway(18). 
9-methylstreptimidone inhibited NO production and iNOS expression in 
lipopolysaccharide-stimulated RAW264.7 macrophage cells and induced apoptosis in 
Jurkat T lymphocytes, similar to other NFκB pathway inhibitors(18). Therefore, 
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9-methylstreptimidone had been suggested as a lead for developing new 
antiinflammatory agents. In this screen, I found that 9-methylstreptimidone restored 
cellular ATP levels to ~40% of the positive control (Figure 4-5 A) and slightly reduced 
caspase-3 activity by 20% (Figure 4-5 B). Since 9-methylstreptimidone was annotated 
as an inhibitor of NFκB pathway, it is not surprising that this compound could block the 
apoptotic effect of cytokines. Because of the lack of commercial availability, 
9-methylstreptimidone was not further studied. 
 
Figure 4-5. Effects of 9-methylstreptimidone in dose studies. 9-methylstreptimidone was 
tested in 8 does in duplicate (circles and triangles are two independent experiments) for A) 
cellular ATP levels and B) caspase-3 activity. The median raw signal of the intra-plate NC 
wells was set to a normalized activity value of 0, while the median raw signal of the intra-plate 
PC wells was set to a normalized activity value of 100. C) Chemical structure of 
9-methylstreptimidone. 
 
I also identified BRD0608, synthesized via diversity-oriented synthesis, as a 
novel suppressor of beta-cell apoptosis. It restored cellular ATP levels to ~100% of 
the positive control (Figure 4-6 A) and reduced caspase-3 activity by 70% (Figure 4-6 
B). Because of the interesting chemical and biological properties, BRD0608 was 
75
further studied in other secondary assays. Moreover, analogs of BRD0608 were 
synthesized to improve both potency and maximum effect of the suppressor. In the 
end, one compound, BRD0476, was selected for studies in human islets. BRD0476 
was also used to study the mechanism of action of this series of compounds. 
 
Figure 4-6. Effects of BRD0608 in dose studies. BRD0608 was tested in 8 does in duplicate 
(circles and triangles are two independent experiments) for A) cellular ATP levels and B) 
caspase-3 activity. The median raw signal of the intra-plate NC wells was set to a normalized 
activity value of 0, while the median raw signal of the intra-plate PC wells was set to a 
normalized activity value of 100. C) Chemical structure of BRD0608. 
 
4.3 Identification of BRD0608 and structure-activity relationships 
Diversity-oriented synthesis (DOS) has emerged as a practical strategy to 
assemble compound libraries with a high degree of stereochemical and skeletal 
diversity, serving to augment traditional screening collections of commercially 
available compounds and natural products(19-23). DOS compounds rival natural 
products in terms of complexity (as measured by sp3-content and the presence of 
stereogenic centers)(24-25) yet are designed to be easily modified in order to facilitate 
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downstream chemistry optimization. These principles were highlighted recently by an 
aldol-based ‘build/couple/pair’ (B/C/P) strategy, resulting in a collection of various 
medium- and large-sized rings derived from a common linear intermediate(26). The 
DOS team at the Broad Institute sought to capitalize on this versatile intermediate to 
further increase the diversity of our compound collection. Building on the past success 
with the SNAr reaction for cycloetherification(26), the team aimed to build a library that 
would provide both structure-activity relationships (SAR) and stereochemical 
structure-activity relationships (SSAR) in primary screens for biological activity. 
Coupling this information with the ability to synthesize analogs rapidly, exploiting short, 
modular synthetic pathways, provides a quick and efficient process to optimize hits 
identified in high-throughput screening (HTS). 
  
Scheme 4-1. (a) 2-fluoro-3-nitrobenzoic acid chloride (2), NEt3, DCM, RT, 84-100%. (b) CsF, 
DMF, 85 ºC, 97-99%. (c) 10% Pd/C, H2, EtOH. (d) FmocCl, aq. NaHCO3, dioxane, 65-98% 
over 2 steps. (e) TBSOTf, then HF/pyridine. (f) AllocCl, pyridine. (g) DDQ, pH 7 buffer, 75-89% 
over 3 steps. 
The DOS team within the Chemical Biology Platform at the Broad Institute 
77
originally synthesized the whole library. After the identification of BRD0608, I started 
to synthesize analogs using the same synthesis route. The synthesis of the library 
scaffolds leading to the synthesis of BRD0608 commenced with linear intermediate 1, 
which was accessed by coupling a suitably protected γ-amino acid with an amino 
alcohol, followed by reduction of the resulting amide (Scheme 4-1).Error! Bookmark not 
defined. All stereoisomers of both the γ-amino acid and the amino alcohol were coupled 
together, resulting in the generation of 1a-d and ent-1a-d, allowing for the full 
stereochemical matrix of scaffolds to be synthesized. Acylation of 1a-d with 
2-fluoro-3-nitrobenzoic acid chloride (2) proceeded smoothly to give the precursor to 
the key step, an intramolecular SNAr reaction (Scheme 4-1). Regardless of the 
different stereochemistry in the linear chain, all stereoisomers reacted smoothly with 
cesium fluoride for de-silylation followed by cyclization to give desired 3a-d in 
excellent yield. Functional group manipulation to prepare for solid-phase library 
production was achieved through a step-wise process involving: 1) nitro reduction and 
subsequent protection of the aniline as the Fmoc carbamate, 2) protecting group 
exchange from the incompatible Boc group to an Alloc, and 3) PMB removal to reveal 
the site for immobilization onto solid support. The sequence was high yielding and 
could be carried out on a multi-gram scale. 
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Scheme 4-2. (a) TfOH, DCM; then 4a-d, 2,6-lutidine. (b) 20% piperidine/DMF. (c) N-capping 
(R1): RSO2Cl, RNCO, RCOCl, RCHO or skip (30 building blocks). (d) Pd(PPh3)4, barbaturic 
acid. (e) N-capping (R2): RSO2Cl, RNCO, RCHO, skip (31 building blocks). (f) 15% 
HF/pyridine, THF; TMSOMe. 
 
Immobilization of the scaffold first involved activation of SynPhase Lanterns with 
triflic acid to give the silyl triflate, followed by exposure with the scaffold in the 
presence of 2,6-lutidine (Scheme 4-2). Typical loading levels for the immobilization 
step were 15-18 µmol/Lantern. Removal of the Fmoc-protecting group under standard 
conditions followed by capping with sulfonyl chlorides, isocyanates, acid chlorides, or 
formaldehyde (29 building blocks) introduced the first appendage diversity (R1) at the 
aniline. Palladium mediated Alloc deprotection in the presence of barbaturic acid 
revealed the second appendage diversity site (R2) at the amine, which was capped 
with sulfonyl chlorides, isocyanates, acids, or aldehydes (31 building blocks). Release 
from solid support was achieved with HF/pyridine, yielding an average of 14.1 µmol of 
each final compound per Lantern. All possible combinations of building blocks were 
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used for each stereoisomers to afford a 7384-membered library. All compounds were 
analyzed by ultraperformance liquid chromatography (UPLC) and those samples with 
purity >75% at 210 nm (6408 compounds, 87% pass rate) were submitted for HTS. 
The SNAr-based library was included with other DOS and commercial libraries in 
a HTS campaign designed to identify suppressors of cytokine-induced beta-cell 
apoptosis. Several DOS compounds partially restored beta-cell viability in the 
presence of these cytokines, and I was able to determine some SSAR features from 
the primary assay (Figure 4-7). Lactams 4c and ent-4d were the preferred 
stereoisomers demonstrating the importance of the stereochemistry within the 
8-membered ring. The 5R,6R stereochemistry was required for activity while the 
configuration of the exocyclic stereocenter was less critical. Urea substituents 
appeared to be favored at the aniline position, compared to sulfonamides and amides. 
At the amine position, sulfonamides resulted in greater ATP levels compared to ureas 
and amines. (2S,5R,6R)-5, BRD0608, was the most potent member of the library, with 
an EC50 of 4.9 µM in restoring beta-cell viability. 
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 Figure 4-7. Performance of the SNAr library in the primary screen. The highlighted blocks 
represented the top-scored compounds identified in the primary screen. 
 
4.4 Synthesis of analogs and discovery of BRD0476 
Using BRD0608, 5, as a starting point, additional SAR was explored via the 
preparation of a variety of analogs and subsequent testing for the restoration of 
cellular ATP levels in INS-1E cells as a readout. We first explored the nature of the 
urea substituent at R1. Based on primary screening results, the bulky naphthyl 
substituent appeared to be preferred over simple phenyl groups, thus we focused on 
subtle modifications to the naphthyl ring. Biological activities of all synthesized 
analogs are in Appendix 1. As shown in Table 4-1, saturation of the naphthyl ring was 
not tolerated (compounds 6 and 7), nor was replacement with a benzofuran ring 
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(compound 8). We next explored modifications to the sulfonamide at R2. When the 
para-methoxyl group was moved to either the ortho- or meta-position (compound 9 
and 10), the activity was abolished. Replacement with a more bulky phenoxy group  
 
Table 4-1. EC50 (µM) and maximum activity of synthesized analogs in restoring 
cytokine-induced β-cell death. 
(compound 11) also resulted in a loss of activity. Potency was retained and even 
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increased with the introduction of a m,p-disubstituted analogs (compound 12 and 13). 
Compound 13 (BRD0476) in particular was a potent suppressor of beta-cell 
death, resulting in the best performance among all analogs, with an EC50 of 0.78 µM 
and 99% maximum activity. The 2,3-dichlorophenyl urea was also synthesized and 
tested (compound 14) to explore further the replacement of the naphthyl ring, 
however this compound was inactive. Removal of the primary alcohol did not affect 
activity (compound 15 and 16). 
The most potent analog, compound 13 (BRD0476), was chosen for further 
characterization of its effects on different aspects of beta-cell biology. Caspase-3 
activity is normally highly elevated in apoptotic beta cells. Inflammatory cytokines 
induced a 6.5-fold increase in caspase-3 activity (Figure 4-8 A). Treatment with 13 in 
the presence of cytokines reduced caspase-3 activity in a dose-dependent manner. 
IL-1β is known to induce gene expression of nitric oxide synthase (iNOS), an effect 
that is potentiated by IFN-γ.(27) The subsequent formation of NO drives cell death by 
both necrosis and apoptosis. Nitrite production is a surrogate measurement of nitric 
oxide generated by cytokine-treated INS-1E cells, and is measured colorimetrically 
using the Griess reagent (a commercially available mixture of naphthylenediamine 
dihydrochloride and sulfanilamide). Compound 13 induced a dose-dependent 
decrease in the production of nitrite (Figure 4-8 B), although the effect was more 
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modest than caspase-3 activity. Cytokine-mediated beta-cell apoptosis has been 
reported to cause a loss of the mitochondrial membrane potential (ΔΨm). JC-1 is a dye 
commonly used to measure ΔΨm. Mitochondrial membrane potential was reduced 
2.5-fold in the presence of cytokines, and is restored to normal levels by treatment 
with compound 13 (Figure 4-8 C). Finally, glucose-stimulated insulin secretion (GSIS) 
is one of the most important physiological functions of beta cells. After brief starvation  
 
Figure 4-8. Cellular effects of 13 in cytokine-induced β-cell death. A) Effects of 13 on 
caspase-3 activity after 48-h treatment. B) Effects of 13 on the cellular production of nitrite 
after 48-h treatment. C) Effects of 13 on mitochondrial membrane potential after 48-h 
treatment. D) Effects of 13 on glucose-stimulated insulin secretion after 48-h treatment. Data 
represents the mean ± standard deviation of 8 independent wells for insulin secretion and 24 
independent wells for A-C. * indicates p < 0.01 as compared to the cytokine treatment alone. 
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followed by challenge with high (16 mM) glucose levels, beta cells secrete insulin into 
the cell-culture media. GSIS was abolished after two-day treatment with inflammatory 
cytokines; however, simultaneous treatment with 5 µM of compound 13 restored 
GSIS to nearly normal levels (Figure 4-8 D). 
 
4.5 Conclusion 
In summary, I identified novel small-molecule suppressors of cytokine-induced 
beta-cell apoptosis. I chose BRD0608 for further chemistry studies because of its 
interesting SSAR property. These results show that the improved DOS analog 13 
(BRD0476) protected rat beta cells from inflammatory cytokines, and may represent a 
viable strategy to protecting pancreatic beta cells in the context of type-1 diabetes. In 
chapter 5, I will focus on the identification of the lead compound's mechanism of 
action. 
 
4.6 Methods and Materials 
Cell culture and reagents. INS-1E cells (generously provided by Claes Wollheim 
and Pierre Maechler, University of Geneva, Switzerland) were maintained in culture 
medium (RPMI 1640 containing 11 mM glucose, 10% fetal bovine serum, 10 mM 
HEPES, 50 µM 2-mercaptoethanol, 1 mM sodium pyruvate) and cultivated at 37C 
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with 5% CO2 in a humidified atmosphere. Recombinant rat IL-1β and recombinant 
mouse TNF-α were purchased from R&D Systems. Recombinant mouse IFN-γ and 
Griess reagent were purchased from Sigma. CellTiter-Glo and Caspase-Glo 3/7 
reagents were purchased from Promega. JC-1 was obtained from Invitrogen. 
 
High-Throughput Screening for Compounds Affecting Cellular ATP Levels 
INS-1E cells were seeded at 10,000 cells per well using a Multidrop Combi (Thermo 
Labsystems) in white optical 384-well plates (Corning Life Sciences). After overnight 
incubation, medium was removed and 50 µL of RPMI containing 1% FBS and a 
combination of cytokines (10 ng mL−1IL-1β, 50 ng mL−1 IFN-γ, 25 ng mL−1 TNF-α) was 
added to every well. Using libraries of compounds dissolved in DMSO and a 
CyBi-Well pin-transfer robot (CyBio Corp.), 0.1 µL of each compound was added. 
After 48 h, medium was removed and 20 µL of CellTiter-Glo reagent was added. 
Luminescence was measured after 10 min of incubation using an EnVision plate 
reader (PerkinElmer). 
 
Solid-phase synthesis of analogs: 
General Methods: Solid-phase synthesis was conducted on silicon-functionalized 
polystyrene SynPhaseTM Lanterns (L-series). Quality-control Lanterns were included 
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at each synthesis step for reaction monitoring by UPLC (UV 210 nM) after 
HF-cleavage. All reactions were conducted in heavy wall pressure vessels from 
ChemGlass with agitation in New Brunswick Scientific incubator shakers. 
Scaffold loading: The starting material was provided by Dr. Jeremy R. Duvall from 
Broad Institute. To a flame-dried flask containing silicon-functionalized Lanterns was 
added a freshly prepared solution of TfOH in anhydrous DCM (9.0 equiv, 5 g of 
TfOH/100 mL of DCM) was added. Each flask was shaken at RT for 10 min at which 
time the Lanterns had turned bright orange. The deep red TfOH solution was removed 
via cannula and anhydrous 2,6-lutidine (12.0 equiv relative to Si) was added. Once 
the Lantern color had changed from orange to white, the scaffold (1.2 equiv. relative 
to Si) was added as a solution in anhydrous DCM (0.4 mL/Lantern) and the reaction 
mixture was shaken for 48h overnight. The loading mixture was removed and set 
aside (to recover any unreacted alcohol) and the Lanterns were washed with the 
following solvents for 30 min intervals: DCM, THF, 3:1 THF/IPA, 3:1 THF/H2O, DMF, 
3:1 THF/H2O, 3:1 THF/IPA, THF, DCM. The Lanterns were then dried on a lyophilizer 
overnight prior to sorting.  
Fmoc removal: To a flask containing Lanterns was added a solution of 20% 
piperidine in DMF (0.8mL/Lantern). After shaking at rt for 30 min, the piperidine 
solution was removed and the Lanterns were washed with the following solvents for 
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30 min intervals: DMF, 3:1 THF/H2O, 3:1 THF/IPA, THF, DCM. The Lanterns were 
then dried on a lyophilizer overnight prior to sorting.  
N-Capping/Isocyanates: To each flask containing Lanterns was added DCM (0.8 
mL/Lantern) followed the desired isocyanate (15 equiv). The Lanterns were shaken at 
rt overnight and then washed with following solvents for 30 min intervals: DCM, DMF, 
3:1 THF/ H2O, 3:1 THF/IPA, THF, DCM. The Lanterns were then dried on a lyophilizer 
overnight prior to sorting.  
Alloc removal: To the reaction vessel containing Lanterns, THF (0.8 mL/Lantern) 
was added, followed by Pd(PPh3)4 (1 equiv) and 1,3-dimethylbarbituric acid (30 equiv). 
The flask was sealed and shaken at rt for 1 day. The reaction mixture was removed 
and the Lanterns were washed with DMF until the washings were clear (without any 
yellow color). Subsequently the Lanterns were washed with the following solvents for 
30 min intervals: 3:1 THF/H2O, 3:1 THF/IPA, THF, DCM. The Lanterns were then 
dried on a lyophilizer overnight prior to sorting.  
N-Capping/Sulfonyl Chlorides: To each flask containing Lanterns was added DCM 
(0.8 mL/Lantern) followed by 2,6-lutidine (20 equiv) and the desired sulfonyl chloride 
(35 equiv). The Lanterns were shaken at rt overnight and then washed with following 
solvents for 30 min intervals: DCM, DMF, 3:1 THF/H2O, 3:1 THF/IPA, THF, DCM. The 
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Lanterns were then dried on a lyophilizer overnight prior to sorting.  
Cleavage Protocol: To a 96-well plate containing Lanterns was added a 15% 
solution of HF/pyridine in stabilized THF (350 µL/Lantern). After 2 h the cleavage 
solution was quenched with TMSOMe (700 µL/Lantern) and the contents of each well 
were transferred to a pre-weighed 2-mL vial. The Lanterns were washed with an 
additional 200 µL of stabilized THF (or THF/MeOH) and the solution was transferred 
to the 2-mL vial. The samples were concentrated on a Genevac® solvent evaporation 
system overnight without heating. 
Characterization of active analogs: Chemical characterization of active analogs are 
in Appendix 2. 
 
Measurement of cellular ATP levels. INS-1E cells were seeded at 10,000 cells/well 
using a Multidrop Combi (Thermo Labsystems) in white optical 384-well plates 
(Corning Life Sciences). After overnight incubation, medium was removed and 50 µL 
RPMI containing the treated compound, 1% FBS and a combination of cytokines (10 
ng/mL IL-1β, 50 ng/mL IFN-γ, 25 ng/mL TNF-α) was added to every well. After 
incubation for 48 hr, medium was removed and 20 µL CellTiter-Glo reagent was 
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added. Luminescence was measured after 10-min incubation using an EnVision plate 
reader (PerkinElmer). 
 
Measurement of cellular nitrite production. INS-1E cells were seeded at 10,000 
cells/well using a Multidrop Combi (Thermo Labsystems) in white optical 384-well 
plates (Corning Life Sciences). After overnight incubation, medium was removed and 
50 µL RPMI containing the treated compound, 1% FBS and a combination of 
cytokines (10 ng/mL IL-1β, 50 ng/mL IFN-γ, 25 ng/mL TNF-α) was added to every well. 
After treatment with cytokine and compounds for 48 hr, 10 µL modified Griess reagent 
(1:1 mixture of 1% sulfanilamide in 30% acetic acid and 0.1% N-(1-naphthyl) 
ethylenediamine dihydrochloride in 60% acetic acid) was added to each well. After 
5-min incubation at room temperature, the absorbance at 540 nm was measured 
using an Envision plate reader (PerkinElmer). 
 
Measurement of mitochondrial membrane potential. INS-1E cells were seeded at 
10,000 cells/well using a Multidrop Combi (Thermo Labsystems) in white optical 
384-well plates (Corning Life Sciences). After overnight incubation, medium was 
removed and 50 µL RPMI containing the treated compound, 1% FBS and a 
combination of cytokines (10 ng/mL IL-1β, 50 ng/mL IFN-γ, 25 ng/mL TNF-α) was 
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added to every well. After treatment with cytokine and compounds for 48 hr, 20 µL of 
3.25µM JC-1 was added to each well. After 3hr incubation at 37°C, the cells were 
gently washed three times with 50 µL per well of 1X PBS (with Ca2+ and Mg2+). 
Fluorescence was measured with an EnVision plate reader (PerkinElmer) at the 
rhodamine spectra (excitation/emission 530 nm/580 nm) followed by fluorescein 
(excitation/emission 485 nm/530 nm). The ratio of rhodamine to fluorescein intensity 
was determined and represents the degree of mitochondrial membrane potential. 
 
Caspase-3 activity assay. INS-1E cells were seeded at 5,000 cells/well using a 
Multidrop Combi (Thermo Labsystems) in white optical 384-well plates (Corning Life 
Sciences). After overnight incubation, medium was removed and 50 µL RPMI 
containing the treated compound, 1% FBS and a combination of cytokines (10 ng/mL 
IL-1β, 50 ng/mL IFN-γ, 25 ng/mL TNF-α) was added to every well. After treatment with 
cytokines and compounds for 48 hr, medium was removed and 20 µL Caspase-Glo 
3/7 reagent was added. Luminescence was measured after 2-hr incubation using an 
Envision plate reader (PerkinElmer). 
 
Glucose-stimulated insulin secretion. INS-1E cells were seeded in 96-well plates 
at 20,000 cells/well in 100 µL RPMI and incubated for 48 hr in 100 µL fresh RPMI 
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containing 1% FBS and the cytokine cocktail in the presence or absence of 5 µM 
MS-275. Cells were washed and incubated for 2 hr in KRBH buffer (135 mM NaCl, 3.6 
mM KCl, 5 mM NaHCO3, 0.5 mM NaH2PO4, 0.5 mM MgCl2, 1.5 mM CaCl2, 10 mM 
HEPES, pH 7.4, 0.1% BSA) lacking glucose. Cells were subsequently incubated with 
KRBH buffer containing 2 mM or 16 mM glucose for 1 hr. The supernatant was 
collected for measurement of secreted insulin. Insulin was measured with a rat insulin 
ELISA kit (Alpco). 
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Chapter 5: Mechanistic studies of BRD0476 in suppressing of cytokine-induced 
beta-cell apoptosis 
5.1 Introduction 
In Chapter 4, I discussed the efforts using high-throughput screening to discover 
novel suppressors of cytokine-induced beta-cell apoptosis. Several different classes 
of compounds were identified for their ability to preserve cell viability in the presence 
of the cytokine cocktail. Specifically, BRD0608, a compound synthesized via 
diversity-oriented synthesis, was prioritized due to its interesting biological and 
chemical properties. Follow-up medicinal chemistry efforts led to the synthesis of 
BRD0476, a more potent analog of BRD0608. BRD0476 has an EC50 of 0.78 µM in 
preserving cellular ATP levels of INS-1E cells in the presence of cytokines. Moreover, 
BRD0476 could reduce cytokine-induced caspase-3 activity, increase the 
mitochondrial membrane potential, and decrease nitrite production in a 
dose-dependent manner. Insulin secretion, the most important physiological function 
for beta cells, was also restored by addition of BRD0476. These results show that the 
BRD0476 protects a rat beta-cell line from inflammatory cytokines, and may represent 
a viable strategy to protect pancreatic beta cells in the context of type-1 diabetes. 
Because of the previously promising results of BRD0476 on rat beta cells, I 
wanted to study the effects of BRD0476 on primary human pancreatic islets. 
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Furthermore, since BRD0476 is a novel suppressor of beta-cell apoptosis, I sought to 
determine the mechanism of action in protecting beta cells from cytokine-induced 
apoptosis. I will describe my efforts in these two directions in the following sections. 
 
5.2 Effects of BRD0476 on primary dissociated human islets 
BRD0476 suppresses cytokine-induced apoptosis in INS-1E cells. I wanted to 
know whether its protective effect could be phenocopied in primary human islets. If so, 
the value of BRD0476 as a probe for beta-cell apoptosis would be enhanced. Before 
experimenting on human islets, I wanted to make sure that BRD0476 is selective 
toward cytokine-induced apoptosis, and is not a generic inhibitor of apoptosis. For this 
purpose, I used thapsigargin, tunicamycin, and high glucose as apoptosis inducers in 
INS-1E cells. As described in Chapter 1, these agents can induce ER stress or 
glucotoxicity in pancreatic beta cells. In this experiment, INS-1E cells were treated 
with a series of concentrations of these compounds, as well as either DMSO vehicle 
or 10µM BRD0476. As measured by cellular ATP levels, INS-1E started to die at 
16nM thapsigargin, 16µg/mL tunicamycin, or 125mM glucose (Figure 5-1). Unlike its 
ability to restore cell viability in the presence of cytokines, BRD0476 could not restore 
INS-1E viability in the presence of each of the three apoptosis inducers (Figure 5-1). 
This result suggests that BRD0476 is not a generic apoptosis blocker that can restore 
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cell viability in response of various apoptosis inducers; instead, BRD0476 shows 
selectivity toward cytokine-induced apoptosis in INS-1E beta cells. 
 
 
Figure 5-1. Effects of BRD0476 on beta-cell apoptosis induced by different apoptosis 
inducers. INS-1E cells were treated with 11 different concentrations of A) thapsigargin; B) 
tunicamycin; and C) glucose. ATP measurements were normalized to the no-treatment 
condition. Data represent the mean ± standard deviation of 24 independent wells. 
 
Next, I wanted to study whether the protective effect of BRD0476 in INS-1E cells 
can be translated to primary human islets. It has been reported that primary human 
islets treated with pro-inflammatory cytokines were undergoing apoptosis after 6-9 
days (1-2). In our lab, Deepika Walpita had developed a system for culturing primary 
dissociated human islet cells (Walpita et al., manuscript submitted). Briefly, the 
human bladder cell line HTB9 was cultured in 384-well plates. HTB9 cells secrete 
extracellular matrix (ECM) on the bottom of the wells. After several days of culture, 
HTB9 cells were washed away while leaving ECM on the plates. Human pancreatic 
islets were then cultured on top of the ECM. I used this system to measure the 
apoptotic effect of cytokines in primary human islets. The quality and quantity of 
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human islets have donor-to-donor variability. Therefore, the data generated from 
human islets is not as consistent as in cell-line models. Moreover, since human islets 
contain a mixed population of cells, including insulin-releasing beta cells, 
glucagon-releasing alpha cells, and somatostatin-releasing delta cells, a simple cell 
viability assay may not represent the viability of beta cells alone. In the literature, beta 
cells were found to be more sensitive to cytokines compared to other cell types in the 
islets (3). A cell viability assay would only observe a small decrease in signal in this 
case. For this reason, I decided to use caspase-3 activity as the measurement. The 
addition of cytokines should lead to an increased signal of caspase-3 activity, which is 
easier to detect. Moreover, since beta cells are the only cells that can secrete insulin 
in a glucose-responsive manner, an insulin secretion assay would be another suitable 
assay to measure the viability of beta cells. 
When primary dissociated human islets were treated with the cytokine cocktail 
for six days, caspase-3 activity was elevated nearly 2-fold (Figure 5-2). The same 
trend was observed in islets from two different donors. Addition of BRD0476 reduced 
caspase-3 activity dose-dependently to normal levels (Figure 5-2). Normally, primary 
dissociated human islets secreted 2-3-fold amounts of insulin when challenged with a 
high glucose concentration (Figure 5-3). This fold change is less than that of intact 
islets, but it is still very detectable by ELISA. When islets were treated with the 
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cytokine cocktail for 6 days, insulin secretion was impaired (Figure 5-3). I observed 
this effect in islet samples from two different donors. Addition of BRD0476 fully 
restored the insulin secretion in donor 3 and partially, but significantly, restored the 
insulin secretion in donor 4 (Figure 5-3). BRD0476 seemed to have a better protective 
effect in donor 3 than in donor 4. Nevertheless, BRD0476 appears to have protective 
effects in primary dissociated human islets from several donors. 
 
 
Figure 5-2. Effects of BRD0476 on caspase-3 activity in dissociated human islet cells 
undergoing cytokine-induced apoptosis. Cells were treated with cytokines and different 
doses of BRD0476 for six days. Data represent the mean ± standard deviation of 12 
independent wells. 
 
 
Figure 5-3. 
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Figure 5-3. (Continued) Effects of BRD0476 on glucose-stimulated insulin secretion in 
dissociated human islet cells undergoing cytokine-induced apoptosis. Cells were 
treated with cytokines and different doses of BRD0476 for six days. Data represent the mean ± 
standard deviation of 4 independent wells. 
 
5.3 Genome-wide gene expression profile revealed the JAK-STAT pathway as a 
target for the effects of BRD0476 
Recognition of some of the limitations of target-based drug and probe discovery 
has led to the phenotype-based approach, in which complex biological systems are 
investigated for phenotypic changes upon exposure to small molecules(4-7). The 
subsequent identification of the molecular targets that underlie an observed 
phenotype is not only important for elucidating the mechanisms of action, but will also 
greatly allow efficient structure-activity relationship studies to be carried out in 
follow-up chemistry by use of target-specific assays. Therefore, target identification is 
an important aspect of a phenotypic screen(8-9). 
BRD0476 has shown a great potential in protecting beta cells from 
cytokine-induced apoptosis in both rat INS-1E cells and primary dissociated human 
islets. Since BRD0476 was identified in a phenotypic screen and had no biological 
annotation, I wanted to study the mechanisms of actions for BRD0476. One approach 
to investigate the genes and pathways that BRD0476 interacts with is to use 
genome-wide gene-expression microarrays to look for genes or gene sets that are 
regulated by BRD0476. The underlying principle is to compare the gene-expression 
101
profiles of samples between cytokines alone and cytokines plus BRD0476. The 
difference in mRNA levels may point to genes that are regulated by BRD0476 in the 
presence of cytokines. For this purpose, I treated rat INS-1E cells with 10µM 
BRD0476 for 6, 12, and 48 hours in the presence of cytokines. The detailed 
conditions are shown in Table 5-1 and each condition consisted of three biological 
replicates. 
 
After the indicated treatments, I isolated the RNA from all the samples and 
submitted them to the Genetic Analysis Platform (GAP) at the Broad Institute. The 
GAP team used the Affymetrix rat 230 2.0 array for acquiring gene-expression data. 
The information about each probe on the chip is extracted from the image data by 
image analysis software. The information is stored in the CEL file. The CEL file, 
provided by the GAP team, includes an intensity value, standard deviation of the 
intensity, the number of pixels used to calculate the intensity value, a flag to indicate 
an outlier as calculated by the algorithm, and a user defined flag indicating the feature 
Table 5-1. Time doses and treatments for all 
microarray samples 
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should be excluded from future analysis. After I processed the CEL files and 
converted the expression of each probe to fold changes over the mean signal of the 
no cytokine control, I first looked at the number of genes that are regulated 
significantly by BRD0476 alone. Very few genes were regulated by BRD0476 in the 
absence of cytokines (Scheme 5-1). Among 20,494 genes tested, only 15 genes were 
up-regulated and 2 genes were down-regulated greater than 2-fold after 6-hour 
treatment. At 12 hours, only 7 genes were up-regulated and 5 genes were 
down-regulated more than 2-fold. As a comparison, 147 genes were up-regulated and 
417 genes were down-regulated more than 2-fold in the presence of cytokines after 6 
hours, and at 12 hours, 381 genes were up-regulated and 739 genes were 
down-regulated more than 2-fold by cytokines. This result indicates that BRD0476 
has little effect on regulating gene expression in normal conditions. However, in the 
presence of pro-inflammatory cytokines, BRD0476 regulates more genes. 
 
 
I then decided to use Gene-Set Enrichment Analysis (GSEA) to look for gene 
sets that are regulated by the addition of BRD0476. GSEA is a computational method 
Scheme 5-1. Numbers of genes up- and 
down-regulated by BRD0476 in the absence 
and presence of cytokines. 
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that determines whether an existing defined set of genes shows statistically 
significant, concordant differences between two biological states (10). The method 
derives its power by focusing on gene sets, groups of genes that share common 
biological function, chromosomal location, or regulation. Since single-gene analysis 
may find little similarity between two independent samples or may miss other 
important effects on pathways, GSEA reveals many biological pathways in common. I 
used GSEA to compare cytokine treatment with cytokines plus BRD0476 at the three 
different time points. mRNA levels are thought to be regulated in a relatively short time 
frame compared to protein levels. Therefore, I expected to see more gene expression 
changes in both 6- and 12-hour treatments. At 48 hours, cells would achieve a new 
homeostasis and some acute changes would probably not been discovered in this 
case. 
The analysis revealed that the top gene sets regulated by BRD0476 in the 
presence of cytokines are gene sets that are related to interferon pathways (Table 
5-2). The same gene sets were observed at all three time points. In the gene set 
“Browne_interferon_responsive_genes” (the set names are annotated by the name of 
the researcher who submits the set), most of the genes are increased by cytokines 
and expressed at lower levels when BRD0476 was added (Figure 5-4 A). These 
genes are all related to the JAK-STAT pathway, which is activated by IFN-γ, one of 
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the three cytokines in the cocktail (Figure 5-4 B). This result shows that BRD0476 
downregulates genes that are activated by IFN-γ, leading to the hypothesis that 
BRD0476 may protect beta cells from cytokine-induced apoptosis by blocking the 
JAK-STAT pathway. 
 
 
 
Table 5-2. Microarray data analyzed by GSEA. Gene sets were ranked by NES (normalized 
enrichment score). NES accounts for differences in gene set size and in correlations between 
gene sets and the expression dataset; therefore, NES can be used to compare analysis results 
across gene sets. The highlighted gene sets are related to interferon pathways. 
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 Figure 5-4. Detailed information on a gene set regulated by BRD0476.  A) Genes in the 
“Browne_interferon_responsive_genes” gene set are mostly correlated in one direction. B) 
Most of the genes are highly expressed in the cytokine alone treatment and expressed at 
lower levels when BRD0476 was added. The highest and lowest fold changes are 12- and 
1-fold relative to the no cytokine control. 
 
As mentioned in Chapter 1, IFN-γ binding to its receptor, IFN-R, induces the 
recruitment of the kinases JAK1 and JAK2. Once activated by phosphorylation, JAK1 
and 2 recruit STAT1 and trigger its activation by phosphorylation. STAT1 then 
homodimerizes and translocates to the nucleus, where it regulates the expression of 
genes containing gamma-activated sequence (GAS) elements in their promoter 
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(Figure 5-5 A). The microarray data suggests that BRD0476 may block the activation 
of the JAK-STAT pathway. To see whether that is the case, I transfected a plasmid 
containing a firefly luciferase gene with six GAS in the promoter region, and a Renilla 
luciferase gene for control (Figure 5-5 B). The Renilla luciferase is driven by a CMV 
promoter; therefore, the signal of Renilla luciferase is proportional to the total number 
of cells. The ratio of luciferase activity from firefly and Renilla luciferases thus reflects 
the transcriptional activity of STAT1. After a 12-hour treatment with cytokines, the 
transcriptional activity of STAT1 was elevated 12-fold compared to the no-cytokine 
control (Figure 5-5 C). In the absence of cytokines, BRD0476 did not change the low 
basal transcriptional activity of STAT1. However, in the presence of cytokines, the 
transcriptional activity of STAT1 was reduced by 60% when 10µM BRD0476 was 
added (Figure 5-5 C). These results are consistent with the microarray data: 
BRD0476 alone has little effect under normal conditions, but it appears to block the 
JAK-STAT pathway in the presence of cytokines. 
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 Figure 5-5. The JAK-STAT pathway and measurement of STAT1 transcriptional activity. 
A) The JAK-STAT pathway is activated by IFN-γ, one of the cytokines added to induce 
apoptosis in this model. (This part of the figure is modified from a figure taken from Cell 
Signaling website.) B) Two plasmids were transfected into INS-1E cells for the measurement 
of STAT1 transcriptional activity. C) Measurement of STAT1 transcriptional activity after 
12-hour treatment with cytokines. 
 
Next, I studied the protein levels of STAT1 by Western blot. The mRNA levels of 
STAT1 were increased by cytokines, and reduced by BRD0476 (Figure 5-4B). By 
protein level, the same trend was observed. STAT1 protein was elevated and reached 
its peak at 12 hours of cytokine treatment (Figure 5-6). When BRD0476 was added, 
the level of STAT1 was moderately reduced (Figure 5-6). There are two main 
phosphorylation sites for STAT1: tyrosine 701 (Y701) and serine 727 (S727). The 
Y701 site is the predominant one for phosphorylation by JAK2. The level of p-STAT1 
at Y701 was elevated as soon as the first hour, and reached its peak at 4 hours 
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(Figure 5-6). The level then reduced back to normal after 4 additional hours. Addition 
of BRD0476 nearly completely blocked the phosphorylation of STAT1 at Y701, with 
only a weak signal observed at 4 hours (Figure 5-6). At the S727 site, the level of 
p-STAT1 was slightly elevated within 4 hours, but the level sustained after 4 more 
hours. Addition of BRD0476 reduced the level after 4 hours. Taken together, 
BRD0476 moderately reduced the protein levels of STAT1 and also blocked the 
phosphorylation of STAT1 at both Y701 and S727. This is consistent with my previous 
results, since STAT1 should not homodimerize and migrate into nucleus in a 
non-phosphorylated form. To show this, I used a nuclear extraction kit to isolate 
nucleus from cytoplasm, using histone H3 as a control for nuclear proteins. Addition of 
cytokines increased STAT1 protein levels in the nucleus (Figure 5-7). STAT1 levels 
were then reduced when BRD0476 was added, although the level did not completely 
return to normal levels (Figure 5-7). In the cytoplasm, addition of cytokines only 
slightly reduced STAT1 protein level (Figure 5-7). This could be explained by a higher 
total STAT1 level in cytokine-treated cells. Therefore, the decrease in the cytoplasm is 
not striking. Addition of BRD0476 also slightly increased STAT1 level in the cytoplasm 
(Figure 5-7). Taken together, these results suggest that BRD0476 inhibits STAT1 
phosphorylation and its migration into the nucleus. 
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5.4 SILAC studies suggested USP9X as a possible primary target for BRD0476 
In the last section, I used genome-wide gene-expression microarray data to 
identify the genes and gene sets that BRD0476 regulates. This led to the hypothesis 
that BRD0476 blocks the JAK-STAT pathway. However, I still did not know the direct 
cellular binding target(s). Uncovering direct targets would not only help to understand 
the mechanisms of action for BRD0476, but would also significantly aid follow-up 
medicinal chemistry studies. For this purpose, I collaborated with the Proteomics 
Platform at the Broad Institute to take a quantitative proteomics approach to identify 
potential cellular binding proteins. 
The Proteomics Platform has adapted a robust and unbiased method for 
probing the proteins that bind to the small molecule of interest in a biologically 
Figure 5-6. Western blots of 
STAT1 and phosphorylated STAT1 
after 10µM BRD0476 treatments. 
Figure 5-7. Western blots of 
STAT1 in nucleus and cytoplasm. 
The concentration of BRD0476 is 10µM.  
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relevant setting. This method, Stable Isotope Labeling by Amino acids in Cell culture 
(SILAC), is a powerful approach in mass spectrometry (MS)-based quantitative 
proteomics (Figure 5-8) (11-13). SILAC labels cellular proteomes through normal 
metabolic processes, incorporating non-radioactive, stable isotope containing amino 
acids in newly synthesized proteins. Growth medium is prepared where natural 
(‘light’) arginines are replaced by ‘heavy’ C13 and N15 arginines. INS-1E cells grown in 
this medium incorporate the heavy amino acids after seven to eight cell passages and 
the heavy amino acids have no effect on cell morphology or growth rates. When light 
and heavy cell populations are mixed, they remain distinguishable by MS, and protein 
abundances are determined from the relative MS signal intensities. 
 
Figure 5-8. Steps for target identification using Stable Isotope Labeling 
by Amino acids in Cell culture (SILAC) and quantitative proteomics. After the 
incorporation of special amino acids, both lysates were incubated with the bait, but 
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(Figure 5-8. continued) excess free CR-6 was added to one lysate, to competitively 
displace target proteins. The beads from both lysates were then washed, combined, 
and proteins that remained bound to the immobilized small molecule were eluted off. 
Eluted proteins were separated using gel electrophoresis. Proteins were trypsin 
digested and analyzed on a mass spectrometer. This figure was modified from a 
figure made by Dr. Shao-En Ong at the Broad Institute. 
 
In order to “pull down” binding proteins, generation of the affinity reagent (bait) 
is a critical first step, which involves tethering the BRD0476 to solid support. The 
synthesis of this bait was performed by Dr. Eamon Comer and Ms. Claire Reddy in 
the Chemical Biology Platform. In Chapter 4, I described the structure-activity 
relationship (SAR), which suggested that the alcohol group in the side chain of 
BRD0476 is not crucial for the protective effect of BRD0476. Therefore, a PEG linker 
was placed at this position, and CR-6 was synthesized in two steps from BRD0476 
(Figure 5-9). I then tested CR-6 in the cellular ATP and caspase-3 assays to ensure 
that the protective activity was retained. In the presence of cytokines, CR-6 restored 
cellular ATP levels and reduced caspase-3 activity in a dose-dependent fashion, 
similar to BRD0476 (Figure 5-10). After the activity of CR-6 was confirmed, the 
compound was attached to solid support and the resulting bait could be used for 
pull-down studies. 
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Figure 5-9. Synthetic route to the synthesis of CR-6. The side-chain hydroxyl 
group was first activated by 1,1’-carbonyldiimidazole and followed by nucleophilic attack of the 
Boc-protected amine. Acid-catalyzed removal of the Boc group gave CR-6. 
 
 
Figure 5-10. Effects of CR-6 on cytokine-induced beta-cell apoptosis.  Cells 
were treated for two days and tested for A) cellular ATP levels and B) caspase-3 activity. 
 
The proteomics team then used SILAC-labeled INS-1E lysates in pull-down 
experiments. Both lysates were incubated with the bait, but 30-fold excess free CR-6 
was added to one lysate, to competitively displace target proteins. The beads from 
both lysates were then washed, combined, and proteins that remained bound to the 
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immobilized small molecule were reduced by DTT and alkylated by iodoacetylamide. 
Proteins were then eluted by LDS buffer and separated by molecular weight using gel 
electrophoresis. The entire gel lane was then cut into several bands to simplify the 
process, and proteins were trypsin digested and analyzed on a mass spectrometer. 
The proteomics team then identified and compared the relative enrichment of target 
proteins, generating differential SILAC ratios between the two states (Table 5-3). 
Each protein’s rank is based on the fold enrichment, which is then converted to a 
p-value. The list here includes all the proteins that have a p-value less than 0.05. 
There were two importins and one exportin in the list, which are involved in nuclear 
transport. 
 
Table 5-3. A list of proteins pull down by CR-6. Proteins are ranked by fold 
changes. The fold change is calculated between the signals of the protein in the absence and 
presence of soluble competitor, CR-6.  
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I decided to use siRNAs to knock down individual genes from the protein list, to 
test whether the knock-down can phenocopy the protective effect of BRD0476. The 
rationale is based on the hypothesis that BRD0476 is a direct inhibitor of a particular 
target. On the other hand, I also wanted to test whether the protective effect of 
BRD0476 would be impaired if a protein was knocked down. Therefore, if BRD0476 is 
an activator of a given protein, I would expect to see no protective effect for BRD0476 
if the protein was knocked down. Based on these ideas, I tested a number of proteins 
from the list (Table 5-4). Here, I would like to focus on two of the proteins, Mcm6 and 
Usp9x. 
 
 
 
MCM6, a DNA replication licensing factor, was the top-ranked protein on the list. 
MCM6 acts as component of the MCM2-7 complex, which is the replicative helicase 
essential for DNA replication initiation and elongation in eukaryotic cells (14). 
Therefore, MCM6 is an important protein for DNA replication, but had no reported 
relationship with cytokine signaling pathways. When I knocked down MCM6 (Figure 
Table 5-4. Summary of 
knock-down studies. The effect 
of knock-down was confirmed by 
either qPCR or western blots.  
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5-11 A) and treated INS-1E cells with cytokines, I did not see a restoration of cellular 
ATP levels (Figure 5-11 B). Furthermore, knock-down of MCM6 had no influence on 
the protective effect of BRD0476 (Figure 5-11 C). This result suggested that MCM6 is 
not a direct target that leads to the protective effect of BRD0476. Similar results were 
observed for IPO4, IPO9, XPO1, BLVRA, GAPDH, and CAND1. 
 
 
Figure 5-11. Effects of knocking down MCM6 in cytokine-induced beta-cell 
apoptosis . A) Validation of siRNAs using quantitative PCR . B) Effects of MCM6 
knock-down on ATP levels in the presence of cytokines. C) Effects of MCM6 knock-down on 
ATP levels in the presence of cytokines and 10µM BRO0476. 
 
USP9X is a member of the peptidase C19 family and is a deubiquitinase. 
Though this gene is located on the X chromosome, it is one of the 15% of genes that 
escape X-inactivation. It is involved in the processing of both ubiquitin precursors and 
of ubiquitinated proteins (15-17). Therefore, it may play an important role at the level 
of protein turnover, by preventing degradation of proteins through the removal of 
conjugated ubiquitin. When I knocked down USP9X (Figure 5-12 A) and treated 
INS-1E cells with cytokines, I observed a full restoration of cellular ATP levels (Figure 
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5-12 B) and reduction of caspase-3 activity (Figure 5-12 C). Knocking down USP9X 
also restored mitochondrial membrane potential in the presence of cytokines (Figure 
5-12 D). These effects were observed in three different siRNA constructs. The effect 
of knocking down USP9X is similar to that of BRD0476, suggesting that USP9X may 
be a binding target of BRD0476. 
 
 
Figure 5-12. Effects of knocking down USP9X in cytokine-induced beta-cell 
apoptosis . A) Validation of siRNAs using Western blot. B) Effects of knocking down USP9X 
on ATP levels after 48-h treatment. C) Effects of knocking down USP9X on caspase-3 activity 
after 48-h treatment. D) Effects of knocking down USP9X on mitochondrial membrane 
potential after 48-h treatment. Data represents the mean ± standard deviation of 24 
independent wells for B-D. * indicates p < 0.01 as compared to the cytokine treatment alone. 
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Next, I wanted to see whether there is direct binding between USP9X and 
BRD0476. One way to do that is to use the normal lysate and bait to do a 
low-throughput pull-down assay. I used CR-6-beads as the bait and unloaded beads 
as a negative control. After washing, I boiled the sample and ran a Western blot using 
a USP9X antibody. USP9X was pulled down by the bait but not the control beads 
(Figure 5-13). However, when I added 5 to 40µM BRD0476 as a soluble competitor, I 
saw only a small decrease in the band intensity. This result may be due to the poor 
solubility of BRD0476 in aqueous solution, and the fact that Western blotting is not as 
sensitive as MS methods. Nonetheless, this served as an independent experiment to 
show that USP9X binds BRD0476. However, this result is not strong enough to 
definitively conclude that USP9X is a direct binder of BRD0476. 
 
 
 
In order to further show direct binding, I tried to make recombinant USP9X 
protein, which turned out to be extremely difficult. USP9X is a 295-kD protein. 
Therefore, simple organisms such as bacteria could not be used as the host for 
Figure 5-13. USP9X was pulled 
down by CR-6.  
Cell lysate was preincubated with 
BRD0476 for 1 hour before shaken 
with beads overnight. BRD0476 
cannot be added more due to poor 
solubility in aqueous solution. 
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expression. I was fortunate to obtain a HEK293 cell line containing a 
tetracycline-inducible USP9X-expression plasmid from Dr. Dario Alessi at University 
of Dundee, Scotland (18). I cultured this cell line, used blasticidin and hygromycin B 
for selection, added tetracycline to induce expression, and lysed cells for protein 
purification. The purification process was challenging because both the induction 
efficiency and the protein yield were quite low. I finally arrived at a fraction that was 
“relatively pure”. This fraction still had several bands, one of which was USP9X 
(Figure 5-14 A). 
Using this fraction, I tested the binding between USP9X and BRD0476 using a 
the thermal shift assay. Ligand binding to a target protein can either stabilize or 
destabilize a protein's native state, as shown by the increase in the bound protein's 
melting temperature (19). The midpoint of the melting curve of a protein will either 
increase or decrease in the presence of ligands (Figure 5-14 B). The temperature 
where the midpoint of the melting curve of a protein happens is the melting 
temperature, Tm. Using this assay, I found that BRD0476 decreased the melting 
temperature of the protein fraction by 1.4 degrees compared to the control (Figure 
5-14 C). Normally, a shift larger than 1 degree will be considered significant. 
Therefore, 1.4 degrees of shift is considered a significant shift for thermal shift assays. 
WP1130, a reported nonselective deubiquitinase inhibitor (20), also decreased the 
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melting temperature by 2.1 degrees (Figure 5-14 C). However, I cannot test the 
protective effect of WP1130 on cytokine-induced beta-cell apoptosis because 
WP1130 alone is toxic to INS-1E cells as low as 1µM. This result suggests that at 
least one component of the protein mixture binds BRD0476. Based on the positive 
control from WP1130, it strongly suggests that USP9X is a direct binder of BRD0476.  
 
Figure 5-14. Thermal-shift assay to detect protein bindings.  A) Silver stain of 
the protein fraction and a Western blot using a USP9X antibody. B) A representative melting 
curve. X-axis is the temperature; Y-axis is the fluorescence from the dye, Nile red. C) 
Summary of the melting temperature. Data represents the mean ± standard deviation of 3 
independent wells. 
 
Recently, USP9X was found to stabilize MCL1 and thereby promote cell 
survival in colon cancer cells (21). USP9X binds MCL1 and removes the Lys 48-linked 
polyubiquitin chains that normally mark MCL1 for proteasomal degradation. 
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Knockdown of USP9X increased MCL1 polyubiquitination, which enhanced MCL1 
turnover and sensitized cells to the BH3 mimetic ABT-737. If BRD0476 is an inhibitor 
of USP9X, I would expect to see that addition of BRD0476 can also enhance the 
effect of ABT-737 on cancer cell death. Therefore, I treated the colon cancer cell line 
DLD-1 with different doses of ABT-737 in the presence and absence of 10µM 
BRD0476. Addition of BRD0476 to ABT-737 shifted the curve to the left (Figure 5-15) 
in a very similar way as USP9X knock-down. This result strengthens the hypothesis 
that BRD0476 is an inhibitor of USP9X. 
 
 
 
5.5 Relationship between the JAK-STAT pathway and USP9X 
By using gene-expression microarrays, I discovered that BRD0476 is likely to be 
involved in perturbing the JAK-STAT pathway. From a quantitative proteomics 
approach, USP9X appears to be a direct binding target for BRD0476. In the literature, 
Figure 5-15. Killing 
curves of DLD-1 cells 
DLD-1 cells were treated 
with ABT-737 in the 
absence or presence of 
10µM BRD0476 for 2 
days. 
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there is no obvious connection between USP9X and the JAK-STAT pathway. Since 
BRD0476 blocks the phosphorylation of STAT1, I hypothesized that BRD0476 might 
be a JAK inhibitor. I submitted BRD0476 to Millipore to test the effects of BRD0476 on 
100 different kinases, including JAK2 and JAK3. However, BRD0476 did not show 
significant inhibition towards any of the kinases tested (Appendix 3). Moreover, I 
tested the effects of two selective JAK2 inhibitors, SD-1029 and Z3, on 
cytokine-induced beta-cell apoptosis (Figure 5-16). However, they are either too toxic 
or have no protective effects. These results suggest that BRD0476 is not a kinase 
inhibitor and likely blocks the phosphorylation of STAT1 in a more indirect manner. 
 
Figure 5-16. Effects of selective JAK2 inhibitors in cytokine-induced 
beta-cell apoptosis . Effects of JAK2 inhibitors on ATP levels after 48-h cytokine treatment 
for A) SD-1029 and B) Z3. Data represents the mean ± standard deviation of 24 independent 
wells. 
 
I also tried to knock down USP9X in INS-1E cells to study the phosphorylation of 
STAT1. Protein levels of STAT1 did not decrease in USP9X-knockdown cells (Figure 
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5-16). More importantly, knock-down of USP9X did not block the phosphorylation of 
STAT1, at either the Y701 or S727 sites (Figure 5-17). These results seemed to be 
confusing in light of my original results. If USP9X is the primary target for BRD0476, 
knock-down of USP9x should also inhibit STAT1 phosphorylation. Thus, the situation 
appears to be more complicated. A possible explanation is that the two events are 
independent of each other, and BRD0476 happens to have effects on both USP9x 
and STAT1. Blocking the JAK-STAT pathway is a known approach to suppress 
cytokine-induced beta-cell apoptosis, as demonstrated by Eizirik and coworkers (22). 
However, knock-down of USP9X would represent a novel approach. Another 
explanation is that USP9X deubiquitinates a protein downstream of the JAK-STAT 
pathway. Therefore, the phosphorylation of STAT1 is too upstream to be influenced 
by knock-down of USP9X. Taken together, although the JAK-STAT pathway and 
USP9X were confirmed to related to the protective effects of BRD0476, further studies 
are still required to completely understand the mechanism of action. 
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5.5 Conclusion 
The process of target identification is a challenging but required part of the probe 
discovery process. BRD0476 is a novel compound synthesized via diversity-oriented 
synthesis capable of suppressing cytokine-induced apoptosis in both rat INS-1E cells 
and primary human dissociated islets. However, the mechanism of action was still 
unknown. By using gene-expression microarrays, I discovered that BRD0476 appears 
to inhibit activation of the STAT1 pathway. I further demonstrated that BRD0476 could 
reduce the protein level of STAT1 and block STAT1 phosphorylation. Moreover, 
BRD0476 also blocks the migration of STAT1 into nucleus and, therefore, reduces the 
transcriptional activity of STAT1. From a quantitative proteomics “SILAC” approach, 
USP9X appears to be a direct binding target for BRD0476. I demonstrated that 
knock-down of USP9X could phenocopy the effect of BRD0476. Moreover, BRD0476 
could shift the melting temperature of a protein fraction containing USP9X. The same 
effect was also seen by using a known USP9X inhibitor, WP1130. However, I could 
Figure 5-17. Western blots of 
STAT1 and phosphoSTAT1 
after knocking down USP9X.  
INS-1E cells were treated with 
Usp9x siRNA overnight and 
cultured for two days before 
treated with cytokines for the 
indicated times. 
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not make a connection between JAK-STAT pathway and USP9X. In the future, a 
gene-expression profile data of USP9X knock-down cells would help to understand 
the underlying mechanism behind the protective effect. Moreover, a better quality and 
quantity of recombinant USP9X protein could help to develop a biochemical assay to 
prove whether BRD0476 is an inhibitor of the enzymatic activity of USP9X. Also, 
global analysis of ubiquitinated proteins would also be helpful to look for substrates of 
USP9X that are related to the protective effects of BRD0476. In conclusion, BRD0476 
suppresses cytokine-induced beta-cell apoptosis by blocking interferon-induced 
STAT1 activation. Moreover, USP9X is a putative direct binding target for BRD0476. 
Knock-down of USP9X phenocopies the effects of BRD0476. However, detail 
connections between the two targets are still unknown. The discovery of USP9X as a 
target to suppress cytokine-induced beta-cell apoptosis could help future screening 
using USP-9X in a target-based screening approach. 
 
5.6 Methods and Materials 
Cell culture and reagents. INS-1E cells (generously provided by Claes Wollheim 
and Pierre Maechler, University of Geneva, Switzerland) were maintained in culture 
medium (RPMI 1640 containing 11 mM glucose, 10% fetal bovine serum, 10 mM 
HEPES, 50 µM 2-mercaptoethanol, 1 mM sodium pyruvate) and cultivated at 37C 
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with 5% CO2 in a humidified atmosphere. Recombinant human IL-1β, recombinant 
human IFN-γ and recombinant human TNF-α were purchased from R&D Systems. 
CellTiter-Glo, Dual-Glo and Caspase-Glo 3/7 reagents were purchased from 
Promega. Antibodies for USP9X, IPO9, IPO4 and XPO1 were from Abcam. 
Thapsigargin, tunicamycin, blasticidin, hygromycin B, nucleus isolation kit and mouse 
monoclonal antibody to tubulin were from Sigma. Secondary horseradish 
peroxidase-conjugated goat anti-mouse and anti-rabbit antibodies were from Thermo 
Fisher Scientific. Antibodies for STAT1 and p-STAT1 were purchased from Cell 
Signaling. GAS reporter assay kit and rat primers for Mcm6 and Blvrb were from 
SABiosciences. All siRNA constructs were from Dharmacon. WP-1130 was 
synthesized in house by Dr. Mingji Dai. ABT-737 was purchase from Selleck Chem. 
JAK2 inhibitors were from EMD4Biosciences. 
 
Human islet culture. Human islets were obtained through variable sources. The 
purity and viability of human islets are reported to be 80–85% and 86–95%, 
respectively, and the average age of donors was 46 y (range 36–58 y; n = 4). Specific 
data on individual donors is reported below. Islets were washed with PBS and 
incubated in CMRL medium supplemented with 10% FBS, 2 mM glutamine, 100 U/mL 
penicillin, and 100 µg/mL streptomycin. Islets were gently dissociated into a cell 
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suspension by incubating in Accutase (37 °C, 10 min), and seeded in 96-well plates 
containing extracellular matrix secreted by the HTB9 human bladder carcinoma cell 
line (23). 
 
 
 
 
Treatment of human pancreatic islets. Human pancreatic islets were treated at 
with 0.5ng/mL human IL-1β, 50ng/mL human IFN-γ and 25ng/mL human TNF-α for 6 
days in white optical 384-well plates or black 96-well plates (Corning Life Sciences).  
 
Measurement of cellular ATP levels. INS-1E cells were seeded at 10,000 cells/well 
using a Multidrop Combi (Thermo Labsystems) in white optical 384-well plates 
(Corning Life Sciences). After overnight incubation, medium was removed and 50 µL 
RPMI containing the treated compound, 1% FBS and a combination of cytokines (10 
ng/mL IL-1β, 50 ng/mL IFN-γ, 25 ng/mL TNF-α) was added to every well. After 
Donor Source 
Islet 
Purity 
Islet 
Viability Age Gender 
Height 
(cm) 
Weight 
(kg) BMI Ethnicity 
1 U Pitt 85% 95% 36 M 190.5 104 28.7 W 
2 Prodo lab 80% 90% 43 N/A N/A N/A 27.0 N/A 
3 Prodo lab 85% 95% 58 N/A N/A N/A 30.4 N/A 
4 U Penn 85% 86% 47 M 177.0 89.5 28.6 B 
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incubation for 48 hr, medium was removed and 20 µL CellTiter-Glo reagent was 
added. Luminescence was measured after 10-min incubation using an EnVision plate 
reader (PerkinElmer). 
 
Measurement of cellular nitrite production. INS-1E cells were seeded at 10,000 
cells/well using a Multidrop Combi (Thermo Labsystems) in white optical 384-well 
plates (Corning Life Sciences). After overnight incubation, medium was removed and 
50 µL RPMI containing the treated compound, 1% FBS and a combination of 
cytokines (10 ng/mL IL-1β, 50 ng/mL IFN-γ, 25 ng/mL TNF-α) was added to every well. 
After treatment with cytokine and compounds for 48 hr, 10 µL modified Griess reagent 
(1:1 mixture of 1% sulfanilamide in 30% acetic acid and 0.1% N-(1-naphthyl) 
ethylenediamine dihydrochloride in 60% acetic acid) was added to each well. After 
5-min incubation at room temperature, the absorbance at 540 nm was measured 
using an Envision plate reader (PerkinElmer). 
 
Measurement of mitochondrial membrane potential. INS-1E cells were seeded at 
10,000 cells/well using a Multidrop Combi (Thermo Labsystems) in white optical 
384-well plates (Corning Life Sciences). After overnight incubation, medium was 
removed and 50 µL RPMI containing the treated compound, 1% FBS and a 
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combination of cytokines (10 ng/mL IL-1β, 50 ng/mL IFN-γ, 25 ng/mL TNF-α) was 
added to every well. After treatment with cytokine and compounds for 48 hr, 20 µL of 
3.25µM JC-1 was added to each well. After 3hr incubation at 37°C, the cells were 
gently washed three times with 50 µL per well of 1X PBS (with Ca2+ and Mg2+). 
Fluorescence was measured with an EnVision plate reader (PerkinElmer) at the 
rhodamine spectra (excitation/emission 530 nm/580 nm) followed by fluorescein 
(excitation/emission 485 nm/530 nm). The ratio of rhodamine to fluorescein intensity 
was determined and represents the degree of mitochondrial membrane potential. 
 
Caspase-3 activity assay. INS-1E cells were seeded at 5,000 cells/well using a 
Multidrop Combi (Thermo Labsystems) in white optical 384-well plates (Corning Life 
Sciences). After overnight incubation, medium was removed and 50 µL RPMI 
containing the treated compound, 1% FBS and a combination of cytokines (10 ng/mL 
IL-1β, 50 ng/mL IFN-γ, 25 ng/mL TNF-α) was added to every well. After treatment with 
cytokines and compounds for 48 hr, medium was removed and 20 µL Caspase-Glo 
3/7 reagent was added. Luminescence was measured after 2-hr incubation using an 
Envision plate reader (PerkinElmer). The same protocol was used for human 
pancreatic islets. 
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RNA interference and Western blotting. siRNAs (100 nM) were transfected into 
INS-1E cells (5,000 cells/well in a 384-well plate) using DharmaFECT reagent. 
Transfected cells were cultured for 72hr, then collected for Western blot analysis and 
cell-based assays. For Western blotting, cells were lysed in RIPA buffer. Total protein 
was separated by 4-12% SDS-PAGE and transferred to a PVDF membrane. Blots 
were developed using the chemiluminescence detection system SuperSignal 
(Thermo Fisher Scientific) and light emission was captured using an Imaging Station 
4000MM (Carestream). 
 
Quantitative PCR for mRNA levels. Following knock-down by siRNA, cells were 
lysed and RNA was isolated using the RNeasy Mini Kit (Qiagen) according to the 
manufacturer's protocol. RNA was reverse transcribed with random primers using the 
High Capacity cDNA Reverse Transcription Kit with RNase inhibitor (Applied 
Biosystems). Quantitative PCR was performed with Power SYBR Green PCR Master 
Mix (Applied Biosystems) on an Applied Biosystems 7900HT real-time PCR machine 
using primers for rat Mcm6 and Blvrb from SABiociences. 
 
Glucose-stimulated insulin secretion. INS-1E cells were seeded in 96-well plates 
at 20,000 cells/well in 100 µL RPMI and incubated for 48 hr in 100 µL fresh RPMI 
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containing 1% FBS and the cytokine cocktail in the presence or absence of 5 µM 
MS-275. Cells were washed and incubated for 2 hr in KRBH buffer (135 mM NaCl, 3.6 
mM KCl, 5 mM NaHCO3, 0.5 mM NaH2PO4, 0.5 mM MgCl2, 1.5 mM CaCl2, 10 mM 
HEPES, pH 7.4, 0.1% BSA) lacking glucose. Cells were subsequently incubated with 
KRBH buffer containing 2 mM or 16 mM glucose for 1 hr. The supernatant was 
collected for measurement of secreted insulin. Insulin was measured with a rat insulin 
ELISA kit (Alpco). The same protocol was used for human pancreatic islets. 
 
GAS reporter assay. INS-1E cells were transfected with plasmids (GAS reporter 
assay kit) using DharmaFECT reagent according to the manufacturer's protocol 
(SABiosciences) in white optical 384-well plates (Corning Life Sciences). After 
overnight incubation, medium was removed and 50 µL RPMI containing the treated 
compound, 1% FBS and a combination of cytokines (10 ng/mL IL-1β, 50 ng/mL IFN-γ, 
25 ng/mL TNF-α) was added to every well. After treatment with cytokines and 
compounds for 18 hr, luminescence was measure using Dual-Glo according to the 
manufacturer's protocol (Promega). 
 
Purification of recombinant USP9X. For each purification, fifty 25-cm dishes of 
confluent HEK-293 cell lines stably expressing wild-type USP-9X (generously 
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provided by Dr. Dario Alessi, University of Dundee, Scotland) were employed. Cells 
were washed twice with ice-cold PBS and lysed in 1 ml of ice-cold lysis buffer. The 
combined lysates were centrifuged at 26000 g for 30 min at 4 °C and the supernatant 
incubated with 0.2 ml of rabbit IgG–agarose beads (Sigma) for 1 h at 4 °C. The 
IgG–agarose was washed extensively with lysis buffer containing 0.15 M NaCl, then 
with several washes in buffer B prior to incubation with 0.250 ml of buffer B containing 
0.1 mg of TEV protease (Invitrogen). After 3 h at 4 °C ~70–90% of the TAP-tagged 
protein had been cleaved from the IgG–agarose and the eluted protein was incubated 
with 0.1 ml of rabbit calmodulin–Sepharose (Roche) equilibrated in buffer C. After 1 h 
at 4 °C, the calmodulin–Sepharose was washed with buffer C. To elute the protein, 
the calmodulin–Sepharose was then incubated with 0.1 ml of buffer D for 10 min at 4 
°C. The eluate was removed from the beads and the elution repeated two or three 
times. To remove the NaCl present in the buffer containing the eluate protein, the 
eluates were centrifuged at 1500 g for 1 min at 4 °C in protein desalting spin columns. 
Lysis buffer contained 50 mM Tris/HCl (pH 7.5), 1 mM EGTA, 1 mM EDTA, 1% (w/v) 
Nonidet P40, 1 mM sodium orthovanadate, 10 mM sodium b-glycerophosphate, 50 
mM sodium fluoride, 5 mM sodium pyrophosphate, 0.27 M sucrose, 1 mM DTT 
(dithiothreitol) and complete proteinase inhibitor cocktail (one tablet/50 ml). Buffer B 
contained 50 mM Tris/HCl (pH 7.5), 0.15 M NaCl, 0.27 M sucrose, 1% (w/v) Nonidet 
132
P40 and 1 mM DTT. Buffer C contained 50mM Tris/HCl (pH 7.5), 0.15 M NaCl, 1 mM 
MgCl2, 1 mM imidazole, 2 mM CaCl2, 0.27 M sucrose and 1 mM DTT. Buffer D 
contained 50 mM Tris/HCl (pH 7.5), 20 mM EGTA, 150 mM NaCl and 5 mM DTT. 
TBS-Tween buffer contained 50 mM Tris/HCl (pH 7.5), 0.15 M NaCl and 0.2% (v/v) 
Tween 20. 
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Appendix 1. Complete EC50 values and maximum activity for all synthesized analogs. 
Entry 
Structure 
 
Cellular activity 
 R1 R2 R3 EC50 (M) Maximum Activity (%) 
1 OH 
 O  
4.89±2.41 62 
2 OH 
  
0.78±0.45 99 
3 OH 
  
3.48±1.40 76 
4 OH 
  
>20 0 
5 OH 
  
>20 0 
6 OH 
  
>20 0 
7 OH 
  
>20 0 
8 OH 
  
>20 0 
9 OH 
  
>20 0 
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10 OH 
  
>20 0 
11 OH 
  
>20 0 
12 OH 
  
>20 0 
13 OH 
  
>20 0 
14 OH 
  
>20 0 
15 OH 
  
>20 0 
16 OH 
  
>20 0 
17 OH 
  
>20 0 
18 OH 
 
>20 0 
19 OH 
  
>20 0 
20 OH 
 
>20 0 
21 OH 
  
>20 0 
22 OH 
 O  
>20 0 
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23 OH 
 O  
>20 0 
24 OH 
N
Me   
>20 0 
25 OH 
  
>20 0 
26 OH 
 O  
>20 0 
27 OH 
  
>20 0 
28 OH 
  
>20 0 
29 OH 
 O  
>20 0 
30 OH 
 
>20 0 
31 OH 
  
>20 0 
32 OH 
 O  
>20 0 
33 OH 
  
>20 0 
34 OH   
>20 0 
35 H 
 O  
3.06±1.41 76 
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36 H 
  
2.79±1.73 89 
139
Appendix 2. Characterization of Active Compounds 
For all the analogs synthesized through solid-phase synthesis, the final amount of each 
analog after purification by HPLC (with >95% purity) is around 1mg, which is not enough 
for detailed chemical characterizations. However, biologically active analogs were 
resynthesized in a larger scale. 1H NMR, 13C NMR and high-resolution mass spec data 
were obtained for these compounds. 
 
N-(((2R,3R)-5-((S)-1-Hydroxypropan-2-yl)-3-methyl-10-(3-(naphthalen-1-yl)ureido)-6-
oxo-3,4,5,6-tetrahydro-2H-benzo[b][1,5]oxazocin-2-yl)methyl)-4-methoxy-
Nmethylbenzenesulfonamide, compound 5 in Table 4-1. 
1H NMR (300 MHz, CDCl3)  8.44 (d, J = 8.0 Hz, 1H), 8.17 (dd, J = 7.5, 18.1 Hz, 2H), 
7.85 (d, J = 7.0 Hz, 1H), 7.69 (d, J = 9.0 Hz, 3H), 7.57-7.41 (m, 3H), 7.13 (dd, J = 7.2, 
16.3 Hz, 2H), 6.98 (d, J = 8.8 Hz, 2H), 4.15 (s, 1H), 3.81 (d, J = 21.9 Hz, 7H), 3.55 (d, J 
= 10.7 Hz, 1H), 3.24 (s, 2H), 3.03 (d, J = 15.3 Hz, 1H), 2.92 (s, 3H), 2.06 (s, 1H), 1.40 (d, 
J = 6.9 Hz, 3H), 0.88 (d, J = 6.7 Hz, 3H). 13C NMR (75 MHz, CDCl3)  169.7, 163.8, 
153.9, 142.8, 134.4, 133.3, 132.5, 131.1, 130.1, 129.2, 128.3, 126.2, 126.0, 125.9, 
125.6, 123.0, 122.7, 122.5, 121.9, 114.7, 85.2, 65.2, 56.1, 55.9, 55.7, 51.9, 38.7, 35.2, 
16.8, 14.4. HRMS (ESI) calcd for C34H38N4O7S [M + H]+: 647.2534, found: 647.2532. 
N-(((2R,3R)-5-((S)-1-Hydroxypropan-2-yl)-3-methyl-10-(3-(naphthalen-1-yl)ureido)-6-
oxo-3,4,5,6-tetrahydro-2H-benzo[b][1,5]oxazocin-2-yl)methyl)-N-methyl-2,3-
dihydrobenzo-[b][1,4]dioxine-6-sulfonamide, compound 13 in Table 4-1.  
 []D20 -14.0 (c 1.0, CHCl3).  1H NMR (CDCl3, 500 MHz)  8.45 (d, J = 8.3 Hz, 1H), 8.23-
8.07 (m, 3H), 7.84 (d, J = 7.7 Hz, 1H), 7.69 (dd, J = 7.8, 14.5 Hz, 2H), 7.57-7.41 (m, 3H), 
7.26 (t, J = 10.1 Hz, 2H), 7.18 (t, J = 7.9 Hz, 1H), 7.11 (d, J = 6.6 Hz, 1H), 6.97 (d, J = 
8.5 Hz, 1H), 4.28 (dd, J = 4.6, 16.9 Hz, 4H), 4.15 (s, 1H), 3.88 (d, J = 8.7 Hz, 1H), 3.83-
3.68 (m, 2H), 3.58 (dd, J = 10.9, 15.6 Hz, 1H), 3.25 (s, 2H), 3.03 (d, J = 15.4 Hz, 1H), 
2.94 (s, 3H), 2.07 (d, J = 7.1 Hz, 1H), 1.41 (d, J = 6.9 Hz, 3H), 0.89 (d, J = 6.7 Hz, 3H). 
13C NMR (CDCl3, 125 MHz)  169.7, 153.8, 148.3, 143.9, 142.7, 134.3, 133.2, 132.4, 
130.9, 129.1, 128.2, 126.9, 126.0, 125.9, 125.9, 125.5, 122.9, 122.6, 121.8, 121.7, 
118.1, 117.4, 85.1, 77.2, 76.9, 76.7, 65.2, 64.5, 64.1, 56.1, 55.9, 51.8, 38.8, 35.1, 16.8, 
14.4.  HRMS (ESI) calcd for C35H38N4O8S [M + H]+: 675.2483, found: 675.2491. 
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N-(((2R,3R)-5-((S)-1-Hydroxypropan-2-yl)-3-methyl-10-(3-(naphthalen-1-yl)ureido)-6-
oxo-3,4,5,6-tetrahydro-2H-benzo[b][1,5]oxazocin-2-yl)methyl)-4-methoxy-
Nmethylbenzenesulfonamide, compound 5 in Table 4-1. 
1H spectrum 
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N-(((2R,3R)-5-((S)-1-Hydroxypropan-2-yl)-3-methyl-10-(3-(naphthalen-1-yl)ureido)-6-
oxo-3,4,5,6-tetrahydro-2H-benzo[b][1,5]oxazocin-2-yl)methyl)-4-methoxy-
Nmethylbenzenesulfonamide, compound 5 in Table 4-1. 
13C spectrum 
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N-(((2R,3R)-5-((S)-1-Hydroxypropan-2-yl)-3-methyl-10-(3-(naphthalen-1-yl)ureido)-6-
oxo-3,4,5,6-tetrahydro-2H-benzo[b][1,5]oxazocin-2-yl)methyl)-N-methyl-2,3-
dihydrobenzo-[b][1,4]dioxine-6-sulfonamide, compound 13 in Table 4-1.  
1H spectrum 
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N-(((2R,3R)-5-((S)-1-Hydroxypropan-2-yl)-3-methyl-10-(3-(naphthalen-1-yl)ureido)-6-
oxo-3,4,5,6-tetrahydro-2H-benzo[b][1,5]oxazocin-2-yl)methyl)-N-methyl-2,3-
dihydrobenzo-[b][1,4]dioxine-6-sulfonamide, compound 13 in Table 4-1.  
13C spectrum 
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Appendix 3 Kinase profiling result of BRD0476 
10M of BRD0476 was tested for duplicates in 100 different kinases which were chosen 
to be representatives for different classes of kinases. The values below are % activity of 
each kinase after incubation of 10M BRD0476. 
Kinases 
BRD0476 @ 10 
µM Kinases 
BRD0476 @ 10 
µM 
Abl(h) 99 MAPK2(h) 111 
ALK(h) 65 MAPKAP-K2(h) 93 
AMPKα1(h) 83 MAPKAP-K3(h) 92 
ASK1(h) 99 MEK1(h) 110 
Aurora-A(h) 104 MKK4(m) 112 
Aurora-B(h) 77 MKK6(h) 103 
Axl(h) 89 MKK7β(h) 103 
BTK(h) 109 MLK1(h) 96 
CaMKI(h) 97 Mnk2(h) 97 
CDK1/cyclinB(h) 104 MSK1(h) 89 
CDK2/cyclinA(h) 105 MSK2(h) 86 
CDK5/p25(h) 101 MST1(h) 100 
CDK6/cyclinD3(h) 106 mTOR(h) 94 
CDK7/cyclinH/MAT1(h) 104 NEK2(h) 102 
CDK9/cyclin T1(h) 112 p70S6K(h) 123 
CHK1(h) 104 PAK2(h) 97 
CK1γ1(h) 92 PDGFRβ(h) 102 
CK1(y) 101 PDK1(h) 102 
CK2α2(h) 113 Pim-1(h) 98 
c-RAF(h) 101 PKA(h) 139 
DRAK1(h) 107 PKBα(h) 98 
eEF-2K(h) 128 PKBβ(h) 92 
EGFR(h) 103 PKBγ(h) 99 
EphA5(h) 108 PKCα(h) 94 
EphB4(h) 101 PKCβII(h) 101 
Flt3(h) 109 PKCγ(h) 99 
Fyn(h) 90 PKCδ(h) 111 
GCK(h) 100 PKCε(h) 110 
GSK3α(h) 137 PKCη(h) 112 
GSK3β(h) 111 PKCι(h) 108 
IGF-1R(h) 86 PKCμ(h) 98 
IKKα(h) 130 PKCθ(h) 115 
IKKβ(h) 97 PKCζ(h) 108 
IR(h) 99 PKG1α(h) 73 
IRR(h) 100 Plk3(h) 103 
IRAK1(h) 96 PRAK(h) 60 
IRAK4(h) 103 ROCK-I(h) 107 
JAK2(h) 108 ROCK-II(h) 97 
JAK3(h) 88 Ros(h) 103 
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JNK1α1(h) 107 Rse(h) 100 
JNK2α2(h) 102 Rsk1(h) 102 
JNK3(h) 109 SAPK2a(h) 96 
KDR(h) 101 SAPK2b(h) 94 
Lck(h) 70 SAPK3(h) 115 
LKB1(h) 85 SAPK4(h) 107 
LOK(h) 103 Src(1-530)(h) 107 
Lyn(h) 102 SRPK1(h) 94 
MAPK1(h) 109 TAK1(h) 101 
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